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Abstract
We have investigated the role of mitofusin proteins in mitochondrial fusion and
Charcot-Marie-Tooth disease Type 2A (CMT2A).  Mitofusins (Mfn1 and Mfn2) are
required for mammalian mitochondrial fusion.  In structure-function analysis, we have
identified loss-of-function mutations in mitofusin GTPase and heptad-repeat domains that
disrupt homotypic and heterotypic domain interactions.  Mutations in Mfn2 cause
CMT2A, a progressive peripheral neuropathy.  We have functionally characterized Mfn2
disease mutations and find that wild-type Mfn1, but not Mfn2, can efficiently
complement nonfunctional CMT2A alleles to restore mitochondrial fusion.  This finding
demonstrates the importance of Mfn1-Mfn2 heterooligomers and suggests that Mfn1
expression is important in determining the cell-type specificity of CMT2A.  To study the
consequences of an Mfn2 CMT2A allele in vivo, we generated transgenic mice that
express Mfn2 T105M in motor neurons.  These animals demonstrate gait impairments
due to distal muscle loss, axonopathy and altered mitochondrial morphology and
distribution in motor neurons.  In a second approach, we have generated CMT2A knock-
in mice by replacing the endogenous genomic Mfn2 with Mfn2 alleles L76P or R94Q.
Preliminary characterizations suggest that heterozygous animals have no disease
symptoms, but homozygous Mfn2 R94Q animals are severely affected.  Together, these
mouse models provide means to assess the pathology of Mfn2 CMT2A alleles and the
role of mitochondrial dynamics in vivo.
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Chapter 1
New functions for mitochondrial dynamics
Scott A. Detmer and David C. Chan
This chapter has been submitted to Nature Reviews Molecular Cell Biology.
1
Introduction
Seminal electron microscopy studies in the 1950s revealed the double-membranes
and cristae that are hallmarks of mitochondria.  These studies of fixed samples led to the
canonical view of mitochondria as bean-shaped organelles, although little was known
about their versatile and dynamic nature.  It is now clear that mitochondria have
drastically different morphologies depending on the cell type.  Even within the same cell,
mitochondria can take on a range of morphologies, from small spheres or short rods to
long tubules.  In fibroblasts, for example, mitochondria visualized with fluorescent
proteins or specific dyes typically form tubules with diameters of approximately 0.5
microns, but their lengths can range from one to ten or more microns.
Even more remarkably, when mitochondria are tracked in living cells, they behave as
dynamic organelles that move constantly and undergo structural transitions.
Mitochondrial tubules move with their long axis aligned along cytoskeletal tracks.
Moreover, individual mitochondria can encounter each other during these movements
and undergo fusion.  Fusion results in merging of the double membranes, resulting in
both lipid and content mixing.  Conversely, an individual mitochondrion can divide by
fission to yield two or more shorter mitochondria.
What are the molecular mechanisms underlying these unusual behaviors, and do
they have consequences for mitochondrial function and cell physiology?  In this review,
we discuss the dynamic nature of mitochondria and summarize the mechanisms that drive
mitochondrial fusion and fission.  In addition, we discuss recent insights into how these
processes affect the function of mitochondria.  Fusion and fission control not only the
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shape of mitochondria, but also the functional capacity of the mitochondrial population,
including its respiratory activity.  Moreover, mitochondrial dynamics plays a key role in
mammalian development, neuronal function and several neurodegenerative diseases, and
apoptosis.
Mitochondria as dynamic organelles
Control of mitochondrial shape by fusion and fission
It is very clear that an important function of mitochondrial fusion and fission is to
control the shape, size, and number of mitochondria (Fig. 1a).  At steady-state, the
frequencies of fusion and fission events are balanced (Nunnari et al., 1997) to maintain
the overall morphology of the mitochondrial population.  When this balance is
experimentally perturbed, dramatic transitions in mitochondrial shape can occur.  Genetic
studies in yeast and mammals indicate that cells with a high fusion-to-fission ratio have
fewer mitochondria that are longer and more highly interconnected (Fig. 2) (Bleazard et
al., 1999; Chen et al., 2003; Sesaki and Jensen, 1999; Smirnova et al., 2001).
Conversely, cells with a low fusion-to-fission ratio have numerous mitochondria that are
small spheres or short rods, often referred to as "fragmented mitochondria."  Such
changes in mitochondrial dynamics are used in vivo to developmentally control
mitochondrial morphology, as during Drosophila spermatogenesis, when many
mitochondria synchronously fuse to form the Nebenkern structure that is required for
sperm motility (Hales and Fuller, 1997).
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Control of mitochondrial distribution by active mitochondrial transport
Mitochondrial transport is required to distribute mitochondria throughout the cell
(Fig. 1b).  In most cells, mitochondria are highly motile and travel along cytoskeletal
tracks.  Mitochondrial transport depends on the actin cytoskeleton in budding yeast
(Fehrenbacher et al., 2004) and on both actin and microtubules in mammalian cells
(Hollenbeck and Saxton, 2005; Ligon and Steward, 2000b; Morris and Hollenbeck,
1995).  Depending of the cellular context, these transport processes serve to ensure
proper inheritance of mitochondria or to recruit mitochondria to active regions of the cell.
For example, in budding yeast, mitochondria are transported into and retained in the
developing bud to ensure mitochondrial inheritance to the daughter cell (Fehrenbacher et
al., 2004).  In neurons, mitochondria are specifically recruited to active growth cones
where demand for ATP is presumed to be great (Morris and Hollenbeck, 1993).
Rates of neuronal mitochondria transport have been reported between 0.4
micron/min (Li et al., 2004) and 0.1-1 micron/sec (Miller and Sheetz, 2004; Morris and
Hollenbeck, 1995; Pilling et al., 2006).  Mitochondria move in a saltatory manner, with
pauses often followed by reversal of direction.  At a given time, 50-75% of mitochondria
are stationary (Bereiter-Hahn and Voth, 1994; Chang et al., 2006; Ligon and Steward,
2000a; Miller and Sheetz, 2004; Morris and Hollenbeck, 1995; Pilling et al., 2006).
These pauses and reversals of direction may reflect attachment and detachment of
cytoskeletal motors.  Although these movements can appear chaotic, several lines of
evidence from neuronal studies suggest that mitochondrial transport is not random.  First,
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neuronal mitochondria most often pause at sites lacking other mitochondria, resulting in a
well-spaced axonal mitochondrial distribution (Miller and Sheetz, 2004).  Second, nearly
90% of mitochondria with high membrane potential move in the anterograde direction,
whereas 80% of mitochondria with low potential move in the retrograde direction (Miller
and Sheetz, 2004).  These results suggest that active mitochondria are recruited to distal
regions with high-energy requirements, whereas impaired mitochondria are returned to
the cell soma for destruction or repair.  Third, mitochondria accumulate at both pre- and
post-synaptic sites in an activity-dependent manner (Chang et al., 2006; Li et al., 2004).
Finally, mitochondria, but not other organelles, accumulate at axonal sites of with high
local nerve growth factor concentration, perhaps related to mitochondrial collection at
active growth cones (Chada and Hollenbeck, 2004; Morris and Hollenbeck, 1993).
Dynamic internal structure
In addition to changes in the overall shape of mitochondria, the internal structures
of mitochondria are also dynamic.  Three-dimensional tomography of cryo-preserved
samples (Mannella et al., 1994; Perkins et al., 1997) has provided new views of
mitochondrial internal structure and its plasticity.  The inner membrane can be divided
into distinct regions:  the inner boundary membrane, the cristae membrane, and the
cristae junctions (Fig. 1c).  The inner boundary membranes are the regions where inner
membrane is in close proximity to the outer membrane.  These regions are likely
important for protein import and may be the sites of coupled outer and inner membrane
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fusion.  The cristae junctions are narrow "neck" regions that separate the inner boundary
membrane from the involuted cristae membrane.
The various regions of the mitochondrial inner membrane are not only
morphologically distinct, they appear to constitute separate functional domains of the
inner membrane.  Proteins involved in translocation of proteins through the inner
membrane, such as the TIM23 complex, are enriched in the inner boundary membrane,
whereas proteins involved in oxidative phosphorylation are enriched in the cristae
membranes (Gilkerson et al., 2003; Vogel et al., 2006; Wurm and Jakobs, 2006).  In
addition, the structure of mitochondrial membranes is linked to the metabolic state of
mitochondria (Fig. 1c).  “Orthodox” cristae morphology, with narrow cristae and few
cristae junctions per cristae compartment, is found in low ATP conditions.  “Condensed”
morphology, with larger cristae having several junctions per cristae, is found in high ATP
conditions (Mannella, 2006).  The conversion between these states likely involves inner
membrane fusion and fission (Mannella, 2006). Taken together, these observations
suggest that inner membrane morphology is dynamically related to bioenergetics,
although the causal relationship remains unclear.
Mechanisms of mitochondrial dynamics
Mediators of fusion
An important inroad into the molecular analysis of mitochondrial morphology
came with the discovery in 1997 of the Drosophila fusion factor fuzzy onions (Fzo), a
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mitochondrial outer membrane GTPase required for the fusion of mitochondria during
spermatogenesis (Hales and Fuller, 1997).  The yeast ortholog, Fzo1, was found to have a
conserved role in mitochondrial fusion (Hermann et al., 1998), and yeast genetics
provided the tools to identify additional modulators of mitochondrial fusion and fission
(Okamoto and Shaw, 2005; Shaw and Nunnari, 2002).  Therefore, the core machineries
mediating mitochondrial fusion and fission are most fully understood in yeast.  Several of
these components have functionally conserved mammalian homologs.  More
comprehensive discussions of the molecular mechanisms of mitochondria fusion and
fission have been presented in recent reviews (Chan, 2006; Griffin et al., 2006).
 In yeast, the core mitochondrial fusion machinery consists of two GTPases, Fzo1p
and Mgm1p (Fig. 3).  Fzo1 is located on the mitochondrial outer membrane and is
essential for fusion of the outer membranes (Hermann et al., 1998; Meeusen et al., 2004).
The mammalian orthologs of Fzo1 are the mitofusins Mfn1 and Mfn2.  These two related
proteins form homo-oligomeric and hetero-oligomeric complexes that are functional for
fusion (Chen et al., 2003).  Mitofusins are required on adjacent mitochondria during the
fusion process, implying that they form complexes in trans between apposing
mitochondria (Koshiba et al., 2004; Meeusen et al., 2004).  A heptad repeat region of
Mfn1 has been shown to form an anti-parallel coiled coil that is likely involved in
tethering mitochondria during fusion (Koshiba et al., 2004).  Mgm1 is a dynamin-related
protein that is essential for fusion of the mitochondrial inner membranes, a function
consistent with its localization to the intermembrane space and association of the inner
membrane (Meeusen et al., 2006).  The mammalian ortholog OPA1 is also essential for
mitochondrial fusion (Chen et al., 2005; Cipolat et al., 2004).  In yeast, the outer
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membrane protein Ugo1 physically links Fzo1 and Mgm1, but no mammalian ortholog
has been discovered.
The membrane potential across the mitochondrial inner membrane, maintained by
the electron transport chain, is essential for mitochondrial fusion (Legros et al., 2002;
Meeusen et al., 2004).  Ionophores that dissipate the mitochondrial membrane potential
cause mitochondrial fragmentation due to an inhibition of mitochondrial fusion (Legros
et al., 2002; Malka et al., 2005).  In an in vitro fusion assay, both the proton and electrical
gradient are important components of the requirement for membrane potential (Meeusen
et al., 2004).  The link between membrane potential and fusion remains to be resolved,
but one factor appears the dependence of OPA1 post-translational processing on the
membrane potential (Ishihara et al., 2006).
Recent work has also identified mitochondrial lipids as important factors in
fusion.  Mitochondrial morphology screens in yeast identified members of the ergosterol
synthesis pathway as being required for normal mitochondrial morphology (Altmann and
Westermann, 2005; Dimmer et al., 2002).  Recently, MitoPLD has been identified as
important for mitochondrial fusion (Choi et al., 2006).  This mitochondrial outer
membrane enzyme hydrolyzes cardiolipin to generate phosphatidic acid.  Interestingly,
erosterol has been linked to yeast vacuole fusion (Fratti et al., 2004), and phosphatidic
acid is thought to play a role in generating membrane curvature required for SNARE-
mediated fusion (Vitale et al., 2001).  Thus, specific lipids may play similar roles in
distinct types of membrane fusion.
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Mediators of fission
The opposing process, mitochondrial fission, requires the recruitment of a
dynamin-related protein (Dnm1 in yeast and Drp1 in mammals) from the cytosol to
mitochondria (Fig. 4).  Both Dnm1 and Drp1 assemble into punctate spots on
mitochondrial tubules, and a subset of these complexes lead to a productive fission event
(Bleazard et al., 1999; Sesaki and Jensen, 1999; Smirnova et al., 2001).  By analogy with
classical dynamin in endocytosis, Dnm1 and Drp1 are thought to assemble into rings and
spirals that encircle and constrict the mitochondrial tubule during fission (Shaw and
Nunnari, 2002).  Consistent with this model, purified Dnm1 indeed can form helical rings
and spirals in vitro, with dimensions similar to those of constricted mitochondria
(Ingerman et al., 2005).  Moreover, Dnm1 assembly is required for fission activity (Bhar
et al., 2006).
Recruitment of Dnm1 to yeast mitochondrial fission sites involves three other
components.   It is dependent on Fis1, a mitochondrial integral outer membrane protein
that is essential for fission (Fekkes et al., 2000; Mozdy et al., 2000; Tieu and Nunnari,
2000).  Fis1 binds indirectly to Dnm1 through either one of two molecular adaptors,
Mdv1 and Caf4 (Fig. 4b) (Griffin et al., 2005).  Either Mdv1 or Caf4 are sufficient to
allow Fis1-dependent recruitment of Dnm1, although Mdv1 has a more important role in
mediating fission.  Fis1 in mammals is also essential for mitochondrial fission (Lee et al.,
2004), but no orthologs of Mdv1 and Caf4 are currently known.  Both Fis1 and Drp1 are
also required for fission of peroxisomes (Koch et al., 2003; Koch et al., 2005).
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Other regulators of morphology
In addition to these core fusion and fission components, other genes can affect
mitochondrial morphology.  For example, genes such as Mmm1, Mdm10, and Mdm12
are required to maintain yeast mitochondria in a tubular shape (Okamoto and Shaw,
2005).  Additional genes have been identified through visual screens for aberrant
mitochondrial morphology in large-scale collections of mutant yeast (Altmann and
Westermann, 2005; Dimmer et al., 2002).  These screens suggest that several cellular
pathways influence mitochondrial morphology and inheritance, including ergosterol
biosynthesis, mitochondrial protein import, actin dynamics, vesicular fusion, and
ubiquitin-mediated protein degradation.  Another fruitful approach has been the
identification of proteins that physically associate with the core components, such as
Mfn2, Mgm1, and Drp1 (Eura et al., 2006; Hajek et al., 2006; Herlan et al., 2003;
McQuibban et al., 2003; Nakamura et al., 2006)}.
Proteins required for mitochondrial transport
Kinesin and dynein microtubule motors are known to be required for anterograde
and retrograde mitochondrial transport, respectively (Hollenbeck and Saxton, 2005).
Recent work has clarified the linkage between mitochondria and the molecular motors.
Screens for essential genes in drosophila identified Milton and dMiro, both of which are
required for anterograde mitochondrial transport in neurons (Guo et al., 2005; Stowers et
al., 2002).  Milton interacts directly with kinesin and associates indirectly with
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mitochondria.  dMiro is a mitochondrial outer membrane protein that interacts directly
with Milton.  Thus, dMiro links Milton and kinesin to mitochondria (Glater et al., 2006).
dMiro contains both GTPase and EF hand domains which are likely important in
regulating mitochondrial transport.
Proteins mediating inner membrane morphology
Studies of mitochondrial inner membrane structure are complicated by the
intimate link, discussed above, between mitochondrial bioenergetics and cristae structure.
Nevertheless, several proteins have been shown to have a specific role in control of
cristae structure.  In addition to their roles in mitochondrial fusion, Mgm1 and OPA1 are
important for cristae structure.  Loss of Mgm1 in yeast or knock-down of OPA1 in
mammalian cells results in disorganized inner membrane structures (Amutha et al., 2004;
Frezza et al., 2006; Olichon et al., 2003; Sesaki et al., 2003).  In both cases, Mgm1 or
OPA1 homo-oligomeric interactions are involved (Frezza et al., 2006; Meeusen et al.,
2006).  The role of OPA1 in cristae structure appears separable from its role in
mitochondrial fusion (Frezza et al., 2006).
Mitochondrial F1FoATP synthase, a rotary enzyme embedded in the inner
membrane that couples proton pumping to ATP synthesis, is essential for normal cristae
structure (Paumard et al., 2002).  This role in inner membrane structure involves a
dimeric form of ATP synthase containing the additional subunits e and g.  As visualized
by electron microscopy, the ATP synthase dimer has a dimeric interface with a sharp
angle that could distort the local lipid membrane.  This distortion may contribute to the
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high membrane curvature that characterizes cristae tubules (Dudkina et al., 2005;
Minauro-Sanmiguel et al., 2005).  Mgm1 is required for oligomerization of ATP
synthase, providing a link between these two modulators of cristae structure (Amutha et
al., 2004).
Additional proteins modulate inner membrane dynamics.  In yeast, Mdm33 is
required for normal mitochondrial morphology, and its over-expression leads to septation
and vesiculation of the inner membranes (Messerschmitt et al., 2003).   Because of these
phenotypes, Mdm33 has been suggested to play a role in inner membrane fission.
Depletion of Mitofilin by RNAi in mammalian cells results in formation of complex
sworls of inner membrane (John et al., 2005).  Depletion of Mmm1p, Mdm31 and
Mdm32, yeast proteins implicated in mtDNA maintenance, also cause aberrant cristae
morphologies (Dimmer et al., 2005; Hobbs et al., 2001).  A challenge for the future will
be determining whether these proteins have direct or indirect effects on cristae
morphology.
Biological functions of mitochondrial dynamics
Mitochondrial fusion and fission were first studied because of their important role
in regulation of mitochondrial morphology.  In addition to this function, it is now clear
that these processes have additional roles in maintaining the health of the mitochondrial
population, with consequences for development, disease, and apoptosis.
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Protection of respiratory function
Cells with abnormalities in mitochondrial fusion have severe mitochondrial
dysfunction in addition to mitochondrial fragmentation.  Mouse fibroblasts lacking either
Mfn1 or Mfn2 show mild heterogeneity in mitochondrial membrane potential (Chen et
al., 2003), although respiratory activity is intact.  Cells lacking both mitofusins, however,
show great heterogeneity in mitochondrial shape and membrane potential and reduced
respiratory capacity (Chen et al., 2005).  Cells lacking OPA1 show similar defects, with
an even greater reduction in respiratory capacity.  Because other cells with fragmented
mitochondria can have normal mitochondrial function, these observations show that
fusion is beneficial to the mitochondrial population apart from its effect on mitochondrial
shape.  Fusion and fission allow the mitochondrial population to form a dynamic network
capable of genetic and biochemical complementation.  Indeed, functional
complementation between mutant mitochondrial DNA genomes has been observed
(D'Aurelio et al., 2004; Ono et al., 2001)
Essential developmental functions
Perturbations in mitochondrial dynamics result in specific developmental defects.
Mice with loss of either mitofusins die in mid-gestation, with Mfn2-null mice showing a
specific defect in placental development (Chen et al., 2003).  Mice lacking OPA1 also die
in early embryogenesis (Alavi et al., 2007).
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Mitochondrial fission is also an essential process.  Worms deficient in
mitochondrial division die before reaching adulthood (Labrousse et al., 1999).  An infant
with a dominant-negative Drp1 allele has been reported.  This patient died at about one
month of age and had a wide spectrum of abnormalities, including reduced head growth,
increased lactic acid, and optic atrophy.  Fibroblasts from this patient showed elongation
of both mitochondria and peroxisomes (Waterham et al., 2007).
Mitochondrial distribution and recruitment in neurons
Mitochondrial dynamics is probably a ubiquitous phenomenon that is important
for all cells.  However, neurons appear to be particularly dependent on proper control of
mitochondrial dynamics.  Abundant mitochondria have been noted at neuronal synapses
since the 1950s (Palay, 1956).  More recent time-lapse imaging has confirmed
enrichment and retention of mitochondria at both pre- and post-synaptic sites (Chang et
al., 2006).  Due to their extreme length (the longest are greater than half a body length),
neurons rely heavily on active transport to recruit organelles, including mitochondria, to
nerve termini.  Fibroblasts lacking the anterograde mitochondrial motor Kif5b have
perinuclearly aggregated mitochondria but no reported functional defects (Tanaka et al.,
1998).  In contrast, disruption of anterograde mitochondrial transport in neurons results in
defective synaptic transmission (Guo et al., 2005; Stowers et al., 2002; Verstreken et al.,
2005).
Fly neurons lacking Milton, Miro, or Drp1 show loss of synaptic mitochondria
and are defective for synaptic transmission (Guo et al., 2005; Stowers et al., 2002;
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Verstreken et al., 2005).  Miro-deficient larvae had altered neuromuscular junctions with
smaller and more abundant pre-synaptic boutons compared to wild-type larvae, indicating
synaptic overgrowth in the absence of productive synapse formation (Guo et al., 2005).
Both mutant Miro and Drp1 synapses were found to have elevated resting Ca2+ levels but
normal Ca2+ dynamics upon moderate stimulation, with more severe defects appearing
during sustained stimulation (Guo et al., 2005; Verstreken et al., 2005).  Both studies
suggest that mitochondria are critically important for Ca2+ homeostasis only during
sustained and intense stimulation.  The more important defect in Drp1 mutants appears to
be decreased synaptic levels of ATP and subsequent immobilization of the reserve vesicle
pool.  Forward-filling of synapses with ATP partially rescued synaptic transmission in
Drp1 mutant neuromuscular junctions (Verstreken et al., 2005).
Mitochondria are also required post-synaptically in dendrites of hippocampal
neurons.  Mitochondrial localization at dendritic spines (potential post-synaptic sites)
increased following repetitive stimulation (Li et al., 2004).  Expression of mutant Drp1
caused elongation of mitochondria and a decrease in both the abundance of dendritic
mitochondria and the density of dendritic spines.  Conversely, over-expression of wild-
type Drp1 decreased mean mitochondrial length and increased both the density of
dendritic mitochondria and spines (Li et al., 2004).  Dendritic spine density was also
increased by creatine, which stimulates mitochondrial activity.
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Involvement in human disease
OPA1 and ADOA
Heterozygous mutations in OPA1 cause autosomal dominant optic atrophy
(ADOA).  This disease is the most common heritable form of optic neuropathy and is due
to degeneration of retinal ganglion cells, whose axons form the optic nerve (Delettre et
al., 2000).  Over 100 mutations in OPA1 have been reported, with the majority of the
mutations occurring in the GTPase domain(Ferre et al., 2005).  Roughly half of the
pathogenic alleles contain nonsense mutations predicted to encode a truncated protein.  A
few nonsense mutations abolish nearly the entire coding sequence(Delettre et al., 2000),
suggesting that haploinsufficiency of OPA1 can cause ADOA.  It remains possible that
other less severe truncations may have dominant-negative activity.
Fibroblasts knocked-down for OPA1 have fragmented mitochondria, defects in
respiration, aberrant cristae structure, and increased susceptibility to apoptosis (Chen et
al., 2005; Cipolat et al., 2004; Griparic et al., 2004; Olichon et al., 2003).  In the disease
state, the pathophysiology remains to be clarified.  Monocytes from a patient with a C-
terminal truncation in OPA1 had aggregated mitochondria (Delettre et al., 2000), and
skin fibroblasts from a patient with a GTPase missense mutation in OPA1 had
fragmented mitochondria and increased sensitivity to apoptosis (Olichon et al., 2006).  In
addition, OPA1 mutations have been associated with reduced ATP production and
mtDNA content (Kim et al., 2005; Lodi et al., 2004).  It is unclear why mutations in
OPA1, which is broadly expressed, have such cell-type specific defects.
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A mouse model of ADOA has been constructed with an OPA1 gene containing a
splice site mutation that causes processed transcripts to lack exon 10 (Alavi et al., 2007).
Although this mutation would be expected to produce an internally truncated protein, the
mutant mice do not produce any detectable protein from the mutant OPA1 gene.
Heterozygous mice show several features of ADOA, including progressive decline in
retinal ganglion cell numbers and loss of axons in the optic nerve.  These results further
support haploinsufficiency of OPA1as a mechanism for ADOA.  Interestingly, mice
homozygous for the OPA1 mutation die at mid-gestation (Alavi et al., 2007), consistent
with an essential requirement for mitochondrial fusion during embryonic development
(Chen et al., 2003).
Mfn2 and CMT2A
Charcot-Marie-Tooth (CMT) disease, one of the most common hereditary
neuropathies, is caused by mutations in at least 30 different genes (Zuchner and Vance,
2006).  Affected individuals have progressive distal motor and sensory impairments
beginning in the feet and hands due to loss of function of long neurons.  Depending on
the type of CMT, these diseases can be caused by a primary defect in the Schwann cells
that myelinate peripheral nerves or in the neurons themselves (Zuchner and Vance,
2006).  CMT2A is an axonopathy caused by the latter defect, and has been associated
with over 40 mutations in Mfn2.  Nearly all of these disease alleles contain missense
mutations or short, in-frame deletions (Zuchner et al., 2004).  Most mutations cluster in
or near the GTPase domain but some also occur in each of the heptad repeat domains of
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Mfn2.  In addition to loss of peripheral nerve function, a subset of CMT2A patients also
have optic atrophy, suggesting a similar mechanistic and clinical outcome for disruption
of mitochondrial dynamics with mutation of OPA1 and Mfn2 (Chung et al., 2006;
Zuchner et al., 2006).
Because of difficulties in studying patient nerve tissue, the pathogenic
mechanisms leading to peripheral nerve degeneration in CMT2A are not well understood.
Only one study has examined ultrastructural defects in mitochondria from nerves of
CMT2A patients.  Mitochondria in the sural nerve of two patients show structural
aberrations in the mitochondrial outer and inner membranes, along with swelling that is
suggestive of mitochondrial dysfunction (Verhoeven et al., 2006).  Aggregation of
mitochondria is also observed.  Interestingly, over-expression of Mfn2 CMT2A alleles
(Baloh et al., 2007; Detmer and Chan, 2007) causes mitochondrial aggregation and
subsequent mitochondrial transport defects in neurons (Baloh et al., 2007).  In fibroblasts,
the mitochondrial aggregation phenotype is dependent on significant over-expression of
the CMT2A alleles (Detmer and Chan, 2007), and therefore its relevance to disease
pathogenesis remains to be clarified.
Several perplexing issues remain to be resolved concerning the molecular genetics
of CMT2A.  How does mutation of one copy of Mfn2 lead to disease?  Why are long
peripheral neurons selectively affected, given that Mfn2 is a broadly expressed protein?
Clues to these issues have come from analysis of CMT2A alleles in mice (Detmer and
Chan, 2007).  Many CMT2A alleles of Mfn2 are nonfunctional for fusion when
expressed alone.  However, the fusion activity of these nonfunctional alleles can be
efficiently complemented by wild-type Mfn1 but not Mfn2.  Because of this
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complementation, in CMT2A patients, cells that express Mfn1 are protected from gross
loss of fusion activity.  In contrast, cells with little or no Mfn1 expression would suffer a
greater relative loss of fusion activity.  In part, these properties of the CMT2A alleles
may underlie the selective loss of sensory and motor neurons.  Consistent with this
model, Mfn2 appears to be more highly expressed in central and peripheral nervous tissue
than Mfn1 (S. A. Detmer and D. C. Chan, unpublished observations).  Even within the
peripheral nerves, it appears that mitochondrial fusion defects are partial, because only
the longest nerves are affected.  Most likely, the extreme dimensions of long peripheral
nerves make them most vulnerable to changes in mitochondrial dynamics.  Hopefully, the
molecular basis of this effect can be dissected in animal models.
GDAP1 and CMT4A
Another form of CMT is associated with defects in mitochondrial dynamics.
GDAP1 (ganglioside-induced differentiation-associated protein 1) is mutated in CMT4A,
one of the few recessive forms of CMT disease.  CMT4A contains both demyelinating
and axonal features, and consistent with this mixed clinical presentation, GDAP1 is
expressed in both Schwann cells and neurons (Niemann et al., 2005).  GDAP1 is an
integral outer membrane protein that likely affects mitochondrial division (Niemann et
al., 2005; Pedrola et al., 2005).  Disease alleles either fail to localize to mitochondria or
are defective in stimulating mitochondrial division when over-expressed (Niemann et al.,
2005).  If GDAP1 disease alleles disrupt normal mitochondrial fission, they may cause
mitochondrial distribution defects similar to those induced by Drp1 mutations discussed
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above (Li et al., 2004; Verstreken et al., 2005).  Again, it will be important determine
whether patient samples substantiate these ideas.
Regulation of apoptosis
A regulated switch in mitochondrial morphology appears to be important for
some forms of apoptosis.  In apoptosis mediated by Bcl-2 family members, the outer
membrane of mitochondria are permeabilized to release contents of the intermembrane
space, such as cytochrome c, into the cytoplasm.  Cytochrome c subsequently activates a
cascade of caspases that propagate and execute the apoptotic program.  This
mitochondrial outer membrane permeabilization is an early step in apoptosis and is
temporally associated with mitochondrial fragmentation (Desagher and Martinou, 2000;
Frank et al., 2001).  In principle, therefore, genes controlling mitochondrial morphology
can potentially impact progression of apoptosis.
The first functional link between mitochondrial fission and apoptosis was the
observation that inhibition of fission can partially block apoptosis (Frank et al., 2001).
Over-expression of dominant-negative Drp1 prevents mitochondrial fragmentation and
reduces membrane depolarization, cytochrome c release, and cell death in response to
apoptotic stimuli (Frank et al., 2001).  Similarly, RNAi-mediated down-regulation of Fis1
and Drp1 inhibits both fragmentation and apoptosis (Lee et al., 2004).  These results
suggest that mitochondrial fission is an important component of mitochondrial
permeabilization and progression of apoptosis.  In addition, over-expression of rat
mitofusin protects against apoptosis, whereas RNAi down-regulation of mitofusin leads
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to fragmentation of mitochondria and increased susceptibility to apoptosis (Sugioka et al.,
2004). Mitochondrial fusion is inhibited during apoptosis following Bax activation
(Karbowski et al., 2004).  Interestingly, Bax, which localizes to discrete puncta on
mitochondria upon induction of apoptosis, colocalize with both Drp1 and Mfn2
(Karbowski et al., 2002).  The functional nature of these interactions is not understood
but suggests that the fission and fusion machinery may be modified in early apoptosis.
Surprisingly, the apoptotic proteins Bax and Bak appear to have a role in normal
mitochondrial morphology.  Bax and Bak double knock-out cells have fragmented
mitochondria due to a fusion defect (Karbowski et al., 2006).  In addition, Bax and Mfn2
interact in a yeast-2-hybrid analysis, and Bax may be involved in Mfn2 distribution on
the mitochondrial outer membrane (Karbowski et al., 2006).
In spite of these compelling observations, the causal relationship of mitochondrial
fission to apoptosis remains to be definitively resolved.  Perplexingly, depending on the
biological system, mitochondrial fragmentation has been reported to occur before
cytochrome c release in some cases, but after in other cases (Arnoult, 2007).  In some
experimental systems, inhibition of mitochondrial fission by knock-down of Fis1 or Drp1
does not inhibit apoptosis, even though mitochondrial fragmentation is efficiently
inhibited (Parone et al., 2006).
In addition to outer membrane permeabilization, remodeling of the cristae
membranes is required for rapid and efficient release of cytochrome c (Goldstein et al.,
2000; Scorrano et al., 2002).  The reason for this requirement is that only a minority
(~15%) of cytochrome c resides in the intermembrane space, with the bulk found in
cristae compartments (Scorrano et al., 2002).  OPA1 appears to be a regulator of cristae
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junctions and therefore cytochrome c release (Cipolat et al., 2006; Frezza et al., 2006).
Over-expression of OPA1 blocks cytochrome c release following induction of apoptosis
by maintaining narrow cristae junctions (Frezza et al., 2006).
Lymphocyte chemotaxis
Mitochondrial dynamics appears to be important for proper mitochondrial
redistribution in lymphocytes during chemotaxis (Campello et al., 2006).  Mitochondria
redistribute to the trailing edge in lymphocyte cell lines migrating in response to chemical
attractants. Modulation of mitochondrial fusion or fission effected both mitochondrial
redistribution and cell migration.  For example, fragmentation of mitochondria enhanced
both redistribution and migration whereas conditions that promoted fusion, and
subsequently larger mitochondria, impaired both redistribution and migration.  These
observations suggest that mitochondrial dynamics is important for recruiting
mitochondria to local cellular areas that have the greatest energy requirements.
Perspectives
The study of mitochondrial dynamics has undergone great advances in the last
few years.  It is now clear that, in addition to control of organelle morphology,
mitochondrial dynamics is important for the functional state of mitochondria.  As a result,
these processes play crucial roles in mammalian development, apoptosis, and disease.  As
our knowledge of mitochondrial dynamics increases, we can expect to learn about its
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involvement in other processes.  The link between defects in mitochondrial fusion and
neurodegenerative disease is particularly intriguing.  In future studies, the
pathophysiological mechanisms underlying such neurodegenerative diseases will
hopefully be dissected in appropriate animal models.
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Figure Legends
Figure 1-1.  Mitochondria as dynamic organelles.  a.  Mitochondrial fusion and fission
control mitochondrial number and size.  When mitochondria fuse, two mitochondria
become a single larger mitochondrion with continuous outer and inner membranes.
Conversely, single mitochondrion can divide to form two distinct mitochondria by
fission.  b.  Mitochondria are distributed throughout the cytoplasm by active transport
along microtubules and actin in mammalian systems.  Distinct molecular motors transport
mitochondria in anterograde or retrograde directions.  c. Inner membrane dynamics.
Cristae are dynamic and can have a variety of different shapes, often in response to the
bioenergetic state of the cell.  OM, outer membrane; IM, inner membrane; IMS, inner
membrane space; IBM, inner boundary membrane; CM, cristae membrane; CJ, cristae
junction.
Figure 1-2.  Mitochondrial fusion and fission determine morphology.  Mitochondrial
morphology is determined by the relative rates of mitochondrial fusion and fission.  In
wild type cells (center), mitochondria form tubules of variable length.  In the absence of
mitochondrial fusion (left), unopposed fission results in fully fragmented mitochondria.
Conversely, decreased fission relative to fusion (right) cause elongated and highly
interconnected mitochondria. Drp1 K38A, dominant-negative form of Drp1; Mfn-null,
cells lacking Mfn1 and Mfn2; scale bar, 10 µm.
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Figure 1-3.  Mitochondrial fusion.  a.  Mitochondrial fusion consists of outer membrane
fusion followed by inner membrane fusion.  Normally these events occur coordinately. .
b.  Dynamin-related proteins Fzo1 and Mgm1 are key molecules in the yeast
mitochondrial fusion machinery.  Fzo1p is an integral outer-membrane protein with
GTPase and heptad repeat domains facing the cytoplasm.  Each domain is required for
fusion activity.  Mgm1 is present on the inner membrane facing the inner membrane
space and is proteolytically processed by a rhomboid protease.  Both long (l-Mgm1) and
short (s-Mgm1) forms are required for mitochondrial fusion.  In addition to inner
membrane fusion, Mgm1 is required for maintenance of cristae structures.  Ugo1 binds to
both Fzo1 and Mgm1 and likely coordinates their function.  All components are nuclearly
encoded.  The mitofusin proteins Mfn1 and Mfn2 are the mammalian homologs of Fzo1;
OPA1 is the mammalian homolog of Mgm1.  No homolog of Ugo1 has been identified.
Figure 1-4.  Mitochondrial fission.  a. Mitochondrial fission is mediated by the dynamin
related protein Dnm1 in yeast.  Cytoplasmic Dnm1 localizes to the mitochondrial outer
membrane where it oligomerizes into a ring structure that constricts and severs the
mitochondrion.  In this model, Dnm1 functions in an analogous manner to dynamin in
endocytosis.  b.  Localization of Dnm1 on the mitochondrial outer membrane is mediated
by Fis1 and the adaptors Mdv1 and Caf4.  Fis1 is an integral outer membrane protein that
interacts with the N-terminus of Mdv1 and Caf4.  In turn, the WD-40 C-terminal domain
of Mdv1 and Caf4 bind to Dnm1.  Fis1 and Dnm1 have mammalian homologs (Fis1 and
Drp1) but no Mdv1 or Caf4 homologs have been identified.
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Thesis Overview
Chapter 2:  Multiple, independent modes of Mitofusin domain interactions are required
for mitochondrial fusion
The mitofusin proteins are required for mitochondrial fusion.  In this chapter, we
describe structure-function and domain interaction analysis of Mitofusin 1 and Mitofusin
2.  We find that mitofusins interact extensively via multiple domains and that the GTPase
domains and heptad-repeat domains are required for mitofusin function and for specific
domain interactions.  We characterize an N- and C-terminal mitofusin interaction by co-
immunoprecipitation and show that it is disrupted by Charcot-Marie-Tooth disease
mutations in Mitofusin 2.
Chapter 3:  Complementation between mouse Mfn1 and Mfn2 protects mitochondrial
fusion defects caused by CMT2A disease mutations
In this work we functionally characterize Mitofusin 2 alleles that cause the
peripheral neuropathy Charcot-Marie-Tooth disease Type 2A.  We find that disease
alleles can be functional or non-functional for mitochondrial fusion.  Significantly, wild-
type Mitofusin 1, but not Mitofusin 2, can functionally complement non-functional
Mitofusin 2 disease alleles.  These results imply that expression of Mitofusin 1 is critical
for the cell-type specificity observed in Charcot-Marie-Tooth disease Type 2A.
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Chapter 4:  Mfn2 disease allele causes gait defects and axonopathy in transgenic mouse
model of CMT2A
In this chapter we report the generation of a transgenic mouse model for Charcot-
Marie-Tooth disease Type 2A (CMT2A) caused by mutations in Mitofusin 2.  We
expressed a Mitofusin 2 disease allele in motor neurons and resulting animals mimic
CMT2A patients in several regards, including gait impairments, lower limb muscle loss
and axonopathy.  Mitochondria in motor neurons expressing the transgene are aggregated
and poorly distributed and are very likely the basis of the animal phenotype.
Chapter 5:  Generation of Mitofusin 2 knock-in mouse models of Charcot-Marie-Tooth
Disease Type 2A
In this chapter we report the generation and initial characterization of knock-in
mouse models of Charcot-Marie-Tooth disease Type 2A (CMT2A).  Using homologous
recombination, we generated mice carrying Mitofusin 2 disease alleles L76P or R94Q at
the endogenous Mitofusin 2 locus.  Thus far, we have not identified defects in
heterozygous animals, which are most relevant to the human disease state, but have found
severe physiological consequences in animals with altered genomic ratios of wild-type
and mutant Mitofusin proteins.
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Chapter 6:  Future Directions
Here, we briefly discuss future lines of investigation based on the work of the
preceding chapters.
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Chapter 2
Multiple Independent Modes of Mitofusin Domain Interactions are Required for
Mitochondrial Fusion
Scott A. Detmer and David C. Chan
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Abstract
Mitofusin 1 and Mitofusin 2 (Mfn1 and Mfn2) are conserved outer mitochondrial
membrane proteins required for mammalian mitochondrial fusion.  Mfn1 and Mfn2 form
homotypic and heterotypic oligomers, but the contributions of the GTPase and heptad
repeat domains to these interactions are poorly understood.  We identify multiple modes
of interaction between Mfn1 and Mfn2 domains including N-terminal and N- and C-
terminal interactions.  Point mutations in the GTPase or either heptad-repeat domains
disrupt domain interactions and result in non-functional full-length molecules.  Mfn2
mutations that cause Charcot-Marie-Tooth Disease Type 2A disrupt the N-C interaction
between Mfn2 N-C but not between Mfn1 C and Mfn2 N.
Introduction
 Mitochondria undergo continuous cycles of fusion and fission and the relative
rates of these opposing reactions determine the mitochondrial morphology within a cell.
These mitochondrial dynamics are required for the maintenance of mitochondrial
function because blocking mitochondrial fusion leads to energetic defects in cells and
embryonic lethality in mice (Chen et al., 2005; Chen et al., 2003).  Two mammalian
mitochondrial fusion factors, Mitofusin2 and OPA1, are mutated in the human
neuropathies Charcot-Marie-Tooth Disease type 2A and dominant optic atrophy,
respectively (Delettre et al., 2000; Zuchner et al., 2004).
The Mitofusin proteins are required for mitochondrial fusion.  Mitofusins are
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nuclearly encoded, integral outer mitochondrial membrane proteins.  They contain a
GTPase domain and two heptad repeat domains, all oriented towards the cytoplasm (Rojo
et al., 2002).  As such, the mitofusins are perfectly positioned to mediate fusion of the
mitochondrial outer membrane.  In mammals there are two mitofusins, Mfn1 and Mfn2,
and each is sufficient to promote mitochondrial fusion (Chen et al., 2003).
Heptad repeat and GTPase domains are key components in other well-characterized
membrane fusion systems.  In SNARE mediated fusion, heptad-repeat mediated coiled-
coil formation drives membrane apposition and is an early step in the fusion reaction.
Associated RAB GTPases are regulatory components of these fusion reactions.
Transmitochondrial tethering mediated by Mfn1 heptad-repeat 2 coiled-coil formation is
an early step in the fusion pathway (Koshiba et al., 2004).  However, it is unclear how
tethered mitochondria proceed in the fusion pathway.
Mitofusins are members of the dynamin superfamily.  Dynamins are large GTPases
that exhibit oligomerization dependent GTPase activity and are involved in a variety of
membrane remodeling systems (Praefcke and McMahon, 2004).  Dynamin family
proteins are known to form complex inter- and intra-molecular interactions.  Mfn1 and
Mfn2 form both homotypic (Mfn1/Mfn1 and Mfn2/Mfn2) and heterotypic (Mfn1/Mfn2)
complexes but the nature of this oligomerization is not well characterized (Chen et al.,
2003; Eura et al., 2003).
Studies on the single budding yeast mitofusin homolog, yFzo1, have revealed that
the GTPase domain and each heptad repeat domain are required for fusion activity
(Griffin and Chan, 2006).  Additionally, allelic complementation between distinct non-
functional yfzo1 alleles demonstrates that yFzo1p functions as an oligomer (Griffin and
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Chan, 2006).  In this study we identify non-functional mutations in the GTPase and
heptad repeat domains of Mfn1 and Mfn2.  We demonstrate that the heptad repeat
domains are required for mitofusin domain interactions and that loss-of-function
mutations disrupt these domain interactions.  We characterize an important mitofusin N-
and C-terminal interaction and show that it is disrupted by Charcot-Marie-Tooth disease
mutations in Mfn2.
Results
The GTPase and heptad repeat domains are required for Mitofusin function
Cell lines lacking both Mfn1 and Mfn2 (Mfn-null cells) have severely fragmented
mitochondrial morphology and are completely deficient for mitochondrial fusion (Chen
et al., 2003; Koshiba et al., 2004).  Overexpression of either Mfn1 or Mfn2 in Mfn-null
cells restores mitochondrial fusion, resulting in tubular mitochondrial morphology (Fig.
1, Fig. 2) (Koshiba et al., 2004).  This defines a system for Mitofusin structure-function
analysis: express mutant Mitofusin in Mfn-null cells and score the resulting
mitochondrial morphology for the presence of tubules.  The definitive test for
mitochondrial fusion activity is the PEG-induced mitochondrial fusion assay (Chen et al.,
2003; Legros et al., 2002); however, we have found excellent agreement between
mitochondrial tubulation in Mfn-null cells and mitochondrial fusion activity in the PEG
experiment (Detmer and Chan, 2007).  It is important to use the Mfn-null cells in this
structure-function analysis in contrast to single Mfn1 or Mfn2 deficient cells due to the
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potential for complementation between the introduced mutant allele and the remaining
endogenous wild-type allele (Detmer and Chan, 2007).
Mitofusins have four identified functional domains:  an N-terminal GTPase
domain and two heptad-repeat domains separated by a transmembrane domain (Fig. 1A,
Fig. 2A).  The transmembrane region passes through the outer mitochondrial membrane
twice such that both the Mitofusin N- and C-termini face the cytosol (Rojo et al., 2002).
We tested the functional importance of the GTPase and heptad-repeat domains by
introducing mutations to these regions and testing for the ability of the mutant Mitofusin
to tubulate mitochondria in Mfn-null cells.   It has previously been reported that the
GTPase domain is critical for Mitofusin function in fly, yeast and mammals (Chen et al.,
2003; Hales and Fuller, 1997).  We have expanded these results by testing additional
GTPase mutations.  The G1 motif (GxxxxGKS) of the GTPase domain is required for
triphosphate nucleotide binding (Bourne et al., 1991).  Mutation of either of the adjacent
glycine and lysine residues in dynamin resulted in a greatly reduced affinity for GTP such
that in vivo the mutant dynamin is predicted to be in the apo form (Marks et al., 2001).
The analogous mutations in Mfn1 (K88A and S89N) result in non-functional alleles (Fig.
1C).  Similarly, these G1 motif mutations in Mfn2 (K109A and S110N) are also non-
functional (Fig. 2C).  Disruption of the G2 motif by the Mfn1 mutation T109A is
similarly non-functional (Fig. 1C).  In dynamin, this mutation permits GTP binding, but
is defective in hydrolysis (Marks et al., 2001).  Each of these Mfn1 mutants (K88A,
S89N, T109A) localize properly to mitochondria as judged by immunofluorescence and
have no effect on the mitochondrial morphology in Mfn-null cells.
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We next tested the importance of the heptad-repeat domains (HR1 and HR2) for
mitofusin function.  Heptad repeats are protein interaction domains that promote
oligomerization by coiled-coil formation.  Substitution of proline residues within a heptad
repeat domain is predicted to preclude coiled-coil formation by disrupting the helical
structure.  Indeed, a dimeric, anti-parallel coiled-coil has been found to form between
Mfn1 HR2 domains and this interaction is disrupted by proline mutations L691P and
L705P (Koshiba et al., 2004).  Experiments with the yeast mitofusin homolog yFZO1
demonstrate that point mutations in HR1 and HR2 can result in complete loss-of-function
molecules (Griffin and Chan, 2006).  We have identified two HR1 mutations that disrupt
function of Mfn1:  L355P is a complete loss-of-function mutation and L380P is partially
functional though it is clearly less efficient at tubulating mitochondria than wild-type
Mfn1 (Fig. 1C).  Both L355P and L380P localize normally to mitochondria.  These
results are shown with the HR2 mutations described previously for comparison (L691P
and L705P, Fig. 1C) (Koshiba et al., 2004).  Similarly, we find that substitution of proline
residues in Mfn2 HR1 (L411P, L417P) and HR2 (L717P, L724P) results in partial or
complete loss-of-function molecules (Fig. 2C).
Non-functional Mitofusin1 point mutants maintain full-length interactions
Mfn1 and Mfn2 form both homotypic and heterotypic oligomers (Chen et al.,
2003; Eura et al., 2003).  That is, Mfn1/Mfn1, Mfn2/Mfn2 and Mfn1/Mfn2 oligomers are
detected in co-immunoprecipitation experiments.  It is not known if these complexes
represent oligomers formed in cis (on the same mitochondria) or in trans (on opposing
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mitochondria, presumably preceding fusion).  Nevertheless, the presence of
oligomerization domains, the demonstrated Mfn1 C-terminal coiled-coil interaction, and
the readily detected interaction between full-length Mitofusins makes it likely that these
interactions are relevant to their function.  Moreover, allelic complementation studies in
yeast demonstrate that the single yeast Mitofusin, yFzo1, functions as an oligomer
(Griffin and Chan, 2006).
One mechanism to explain the loss-of-function phenotype in the Mfn1 and Mfn2
point mutants is that they disrupt oligomerization.  We tested each of the Mfn1 GTPase
and heptad repeat mutants in a co-immunoprecipitation assay for their ability to interact
with themselves (Fig. 2).  C-terminally Myc- and HA- tagged Mfn1 constructs were co-
transfected in 293T cells, cultured for 48 hours, and then lysed and subjected to an anti-
Myc immunoprecipitation.  As a control for non-specific binding of HA constructs during
the immunoprecipitation, we included a transfection that contained no Myc construct.  In
no case did a non-functional mutation disrupt the interaction between full-length
molecules (Fig. 2).  This suggests that Mitofusin oligomerization is achieved through
multiple, redundant interacting domains.
Mitofusins have multiple, distinct domain interactions
In an effort to dissect the mitofusin domains that mediate the full-length mitofusin
interactions, we generated domain fragments and tested them in the co-
immunoprecipitation interaction assay.  We dissected the mitofusins into their soluble N-
and C-terminal fragments such that each fragment lacked transmembrane domain
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residues:  Mfn1 N (residues 1-579) and C (629-741) and Mfn2 N (1-598) and C (648-
758).  We previously reported that Mfn1 C could interact both with itself and with Mfn2
C.  Here, we report that the Mfn1 N and Mfn2 N constructs can form both homotypic and
heterotypic interactions (Fig. 4A).  Thus, two distinct and non-overlapping fragments can
contribute to mitofusin oligomerization:  N-N interactions and C-C interactions.
Two previous reports have demonstrated that the N- and C-terminal domains of
Mfn2 interact.  In the first, expression of a mitochondrially localized C-terminal construct
of Mfn2 containing the transmembrane domain promoted mitochondrial recruitment of an
otherwise cytoplasmic N-terminal fragment (Rojo et al., 2002).  In the second, co-
immunoprecipitation experiments demonstrated that Mfn2 N- and C-terminal constructs
could interact and that they depend on an intact GTPase domain (Honda et al., 2005).
We sought to extend these observations to Mfn1 and to test for heterotypic N- and C-
terminal interactions.
Both Mfn1 and Mfn2 N and C fragments interact with themselves in the co-
immunoprecipitation assay (Fig. 4B).  This is a much stronger interaction than we find in
any other fragment or full-length Mitofusin co-immunoprecipitation experiment.
Additionally, we find that the Mfn1 C-terminus interacts strongly with the Mfn2 N-
terminus, but that the Mfn2 C-terminus does not interact with the Mfn1 N-terminus (Fig.
4B).  This is the only non-reciprocal interaction we detect between Mfn1 and Mfn2 and
the functional significance has yet to be determined.
GTPase and HR1/HR2 fragments of yFzo1p have been shown to co-
immunoprecipitate and functionally complement each other in yeast (Griffin and Chan,
2006). We tested if analogous constructs of mammalian Mfn1 behaved similarly. Co-
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immunoprecipitation experiments between the GTPase and HR1/HR2 fragments of
mammalian Mfn1 and Mfn2 resulted in only very weak binding and no functional
complementation between these fragments was detected (data not shown).  Notably,
yFzo1p has an additional N-terminal heptad repeat domain that is not found in the
mammalian Mitofusin proteins.
Characterization of Mfn1 N- and C-terminal interaction
Mfn1 HR2 forms a dimeric coiled-coil that can be completely disrupted by the
introduction of the L705P mutation in the middle of HR2 (Koshiba et al., 2004).  Using
the L705P mutation, we sought to confirm that the Mfn1 C-terminus binds to the Mfn1
N-terminus.
First, we found that the Mfn1 C (residues 629-741) binds to full-length Mfn1
(Fig. 5A).  This interaction could occur either by the C-terminal fragment binding to the
C-terminus or to the N-terminus of the full-length molecule.  To remove the former
possibility, we tested interaction between Mfn1 C and full-length Mfn1 L705P.  We find
that Mfn1 C binds to the mutant full-length molecule (Fig. 5A) and conclude that this
interaction must be independent of the C-terminus in the full-length molecule.
Furthermore, the interaction between Mfn1 C and Mfn1 L705 is consistently stronger
than the interaction with wild-type Mfn1 suggesting that the L705P mutation is disrupting
an N-terminal binding site in the mutant molecule that is normally occupied by the C-
terminus in wild-type molecules.  In a control reaction, a C-terminal fragment containing
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L705P binds very poorly to wild-type full-length Mfn1, which means that the Mfn1 C
interaction with full-length Mfn1 is largely dependent on the HR2 domain.
To determine the sequence requirements of the N- and C- terminal interactions we
tested incrementally smaller N-terminal fragments (Fig. 5B).  We find little difference in
the strength of interaction between the C-terminus binding to the full N-terminus (1-579)
and GTPase/HR1 (1-453).  However, the C-terminal construct binds to a GTPase
domain-only fragment (1-330) significantly less well than it does to the longer fragments.
Furthermore, deletion of the first 50 residues of either of the longer N-terminal constructs
drastically reduces interaction with the C-terminus (data not shown); this is similar to a
previous finding with Mfn2 (Honda et al., 2005).
Mutations in the GTPase, HR1 and HR2 domains disrupt the N-C interaction
To further characterize the Mfn1 N-C interaction, we tested the effect of
mutations in the GTPase and heptad-repeat domains in the co-immunoprecipitation assay.
For these experiments, we used the Mfn1 N-terminal construct 1-453 as it is the smallest
construct found to retain strong interaction with the C-terminus.  Loss-of-function proline
mutations in HR1 (L355P and L380P) and HR2 (L691P and L705P) strongly disrupt the
N- and C-terminal interaction (Fig. 5C).  Together, these data provide indirect evidence
for an HR1-HR2 interaction as mutation of either domain greatly reduces binding.  We
were unable to test for an HR1-HR2 interaction directly as all HR1 constructs we tested
were expressed at only very low levels.
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GTPase domain mutations in the Mfn1 1-453 construct also disrupt the N- and C-
terminal interaction, though to a lesser extent than the HR1 or HR2 mutations.  The G1
mutations (K88A and S89N) have an intermediate decrease in the interaction compared
to wild-type and the HR point mutations.  The G2 mutation (T109A), though a non-
functional mutation in full-length Mfn1, appears to have only a modest effect on the N-C
interaction.  In Mfn2, a G1 mutation (K109A) has a more severe effect on the N-C
interaction (Fig. 7A, B).
Mfn1 C-GTPase domain interaction
The C-terminus of Mfn1 (629-741) interacts with the GTPase domain (1-330)
much more weakly than it does with the GTPase/HR1 domain (1-453) (Fig. 5B).  We
reasoned that this binding might represent a different mode of interaction due to the
absence of HR1.  Indeed, we found that a shorter HR2-only Mfn1 C-terminal fragment
(660-737) did not interact with the GTPase domain fragment (Fig. 6B).  Furthermore,
HR2 proline mutations L691P and L705P did not disrupt the interaction between the
longer C-terminal fragment (629-741) and the GTPase domain (Fig. 6B).  Together, these
data demonstrate that the relatively weak interaction in Mfn1 between the C-terminus and
the GTPase-only domain does not depend on HR2.  This mode of interaction is likely
responsible for the weak binding observed between the Mfn1 C L705P and full-length
Mfn1 (Fig. 5A).
We examined the residues between 629 and 660 and found several well-
conserved charged residues in Mitofusin proteins (Fig. 6A).  We tested the importance of
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these conserved charged residues by mutating them to alanine and testing them in the
Mfn1 C-GTPase domain interaction.  Mutations E639A, K643A and K653A each
disrupted the C-GTPase interaction (Fig. 6C).  In contrast, K638A and R640A had no
effect on the interaction.  None of these mutations affected the C-GTPase/HR1
interaction (data not shown).
Having found an interaction defect, we asked if these charged residues are
functionally important. We made the charge mutations in full-length Mfn1 molecules and
tested them in Mfn-null and wild-type cells (Fig. 6D-G).  All of the mutant full-length
molecules localized normally to mitochondria and only K643A has clear functional
consequence.  Mfn1 K643A is non-functional for mitochondrial fusion when expressed in
Mfn-null cells (Fig. 6D-E).  Further, it causes dramatic fragmentation of mitochondria
when expressed in wild-type cells (Fig. 6F-G).  Thus, Mfn1 K643A is a non-functional
allele that has dominant mitochondrial fragmentation activity.
Mfn2 CMT2A alleles disrupt N-C interaction
Mutations in Mfn2 cause Charcot-Marie-Tooth disease type 2A (CMT2A), a
peripheral neuropathy that results in loss of the longest motor and sensory neurons.  Over
40 missense mutations have been reported in Mfn2 thus far and the majority of these
cluster in and around the GTPase domain and in HR1 and HR2 (Zuchner et al., 2004).
Only a subset of the mutant Mfn2 alleles have been functionally characterized, and these
include alleles that are functional and non-functional for mitochondrial fusion (Detmer
and Chan, 2007).  A majority of these alleles cause mitochondrial aggregation when
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overexpressed in neurons or fibroblasts (Baloh et al., 2007; Detmer and Chan, 2007).  We
tested if the Mfn2 CMT2A mutations had an effect on the Mfn2 N-C interaction.  Four of
the nine CMT2A alleles tested (L76P, R94W, T105M, P251A) are defective in the N-C
interaction.  The reduction in binding with these CMT2A mutations is comparable to the
low level of binding found with the designed Mfn2 GTPase mutation K109A.  The
remaining CMT2A alleles (V69F, R94Q, R274Q, R280H, W740S) interact at levels
similar to wild-type fragments.  The ability to interact in the N-C interaction assay does
not completely correlate with the CMT2A allele function.  Alleles V69F, R274Q, and
W740S are functional and do interact, whereas R94W, T105M and P251A are non-
functional and do not interact.  However, L76P is a functional allele that does not interact
and R94Q and R280H are non-functional alleles that do interact.  It is surprising that
mutations R94Q and R94W, both of which are non-functional, have different interaction
properties.
We next tested whether the Mfn2 N-terminal CMT2A mutant constructs could
interact with Mfn1 C.  In this assay, the GTPase mutation K109A and CMT2A mutation
T105M have clearly reduced interactions.  However, the remaining CMT2A alleles retain
wild-type or significant levels of interaction.
Discussion
This study confirms and extends the functional importance of the GTPase and
heptad-repeat domains of Mfn1 and Mfn2.  Specifically, mutation of any of these
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domains can result in a non-functional molecule.  Moreover, the heptad-repeat mutations
can be linked to disruption of specific domain interactions within the Mitofusins.
Mitofusin oligomerization is clearly complex as there are multiple modes of
interaction between non-overlapping fragments.  For Mfn1, the N-terminus can interact
with itself, the C-terminus can interact with itself, and the N- and C-termini can interact
with each other.  Furthermore, there is the capacity for significant cross-interaction
between Mfn1 and Mfn2 through the formation of N-N, C-C and N-C interactions.  These
extensive hetero-interactions strongly suggest that when Mfn1 and Mfn2 are both present
in a cell they function coordinately and are likely required for the observed
complementation between wild-type Mfn1 and non-functional Mfn2 mutants (Detmer
and Chan, 2007).
We find that the C-terminus of Mfn1 interacts strongly with an N-terminal
GTPase/HR1 fragment and that this interaction is disrupted by loss-of-function proline
mutations in either HR1 or HR2.  These results imply an HR1-HR2 interaction.  We have
been unable to test this prediction directly as all of the HR1 constructs we made
expressed very poorly.  Mfn1 HR2 is known to dimerize with itself to form an anti-
parallel coiled-coil (Koshiba et al., 2004).  The possibilities that (1) an HR2 dimer could
interact with HR1 to form a larger helical bundle or that (2) HR2 could alternatively
interact with itself or with HR1 are intriguing.  In either case, it seems likely that the
GTPase domain could regulate such interactions.  First, GTPase domain point mutations
designed to decrease GTP binding in Mfn1 and Mfn2 disrupt the N-C interaction.
Second, GTPase domain point mutations behave distinctly from an N-terminal truncation
that removes the GTPase domain.  This construct (residues 331-741) causes
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mitochondrial aggregation that likely represents tethered mitochondria that cannot
proceed to fusion in the absence of the GTPase domain (Koshiba et al., 2004).  Thus,
there is likely a structural requirement for the GTPase domain in addition to its enzymatic
activity.
We find that four of the nine Mfn2 CMT2A alleles tested are defective in the
Mfn2 N-C interaction.  However, there is an imperfect correlation between Mfn2
CMT2A alleles that can interact in the N-C assay and that are functional for
mitochondrial fusion.  Most surprising is allele L76P which is functional but does not
interact; this result suggests that the N-C interaction is not strictly required for mitofusin
function.  However, Mfn2 L76P does induce mitochondrial aggregation, even at low
expression level (Baloh et al., 2007; Detmer and Chan, 2007).  When we test for Mfn1 C
binding to CMT2A allele Mfn2 N we find that seven of eight constructs interact well.
Only Mfn2 N T105M does not interact with Mfn1 C.  Interestingly, T105M is the only
Mfn2 CMT2A allele that is not complemented by Mfn1 in trans (Detmer and Chan,
2007).
In addition to the N-C interaction, we find a distinct interaction between Mfn1 C
and a GTPase-only construct.  This interaction is weaker than the GTPase/HR1
interaction, is independent of HR2 and requires charged residues between the
transmembrane domain and HR2.  Mutation K643A disrupts the Mfn1 C-GTPase
interaction.  In full-length Mfn1, K643A is non-functional for mitochondrial fusion and
causes mitochondrial fragmentation when expressed in wild-type cells.  The K643A
mutation does not disrupt the C-GTPase/HR1 interaction yet has significant functional
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effects, suggesting that this region of Mfn1 has a critical interaction with the GTPase
domain.
Dynamins are large proteins with extensive intra- and inter-molecular
interactions.  Though Mitofusins are most closely related to dynamins in the GTPase
domain, they also share a similar domain structure and organization (Praefcke and
McMahon, 2004).  It remains to be determined if mitofusins, like dynamins, have
assembly-dependent regulation of GTPase activity and if the C-terminus can function as a
GTPase effector domain.  Future structural and biochemical studies of the N- and C-
terminal fragments will be required to precisely define these interactions as well as the
enzymatic and functional consequences relating to mitofusin activity in mitochondrial
membrane fusion.
Experimental Procedures
Cloning
The mitofusin 7xMyc and 3xHA constructs were described previously (Chen et
al., 2003).  Point mutations were introduced by PCR with primers encoding the mutations
to Mfn1-7xMyc or Mfn2-7xMyc constructs in pcDNA3.1.  Mfn1 and Mfn2 fragments
were generated by PCR and cloned into 7xMyc or 3xHA pcDNA3.1 vectors.  In both
cases, the entire region amplified by PCR was verified by sequencing.  Full-length
mutant constructs were subcloned into retroviral pCLBW constructs for functional
testing.
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Cell culture and retroviral transduction
Wild-type MEFs were cultured in DMEM supplemented with 10% BCS, l-
glutamine and Pen/Strep (all from Gibco). Mfn-null MEFs were cultured as above, but
with 10% FCS.  Retroviral supernatants were generated as described (Chen et al., 2003).
All infections were completed at low multiplicity of infection to limit the level of
overexpression (Detmer and Chan, 2007).  Cells were processed for immunofluorescence
approximately one week after retroviral infection.
Immunofluorescence
Immunofluorescence against Myc-tagged mitofusins has been described
previously (Chen et al., 2003).  9E10 primary antibody and Cy3-conjugated secondary
antibody was used to detect the Myc epitope in fixed cells grown on coverslips.  Imaging
was achieved on a Zeiss Pascal laser scanning confocal microscope with a Pan NeoFluar
63x oil immersion objective (N.A. 1.25) and controlled by Zeiss LSM v3 software.
Images were resized in Adobe Photoshop CS.
Co-immunoprecipitation
1.8 micrograms of DNA of Myc and HA pcDNA3.1 constructs were transfected
to 293T cells in 6 well plates using calcium phosphate.  Media was replaced twelve hours
post-transfection and 36 hours later cells were processed.  Cells were lysed in 400
microliters lysis buffer (1X TBS, 1% TX-100, 4mM MgCl2, and 1X protease inhibitor
cocktail (Roche).  Post-nuclear lysates were immunoprecipitated with 9E10 antibody
coupled to protein A sepharose beads.  HA.11 (Covance) and 9E10 antibodies were used
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for immunoblotting.  All gels have immunoprecipitated material at 14 times the relative
load of lysate.
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Figure Legends
Figure 2-1.  Structure-function analysis of Mfn1.  A.  Schematic of Mfn1, with domains
and mutations (HR, heptad repeat; TM, transmembrane).  Position of domains indicated
by residue numbers below schematic.  B.  Representative images of Mfn1-Myc constructs
expressed in Mfn-null cells by retroviral infection.  Mitochondria are labeled with EGFP
(green) and Mfn1 is labeled by immunofluorescence against the Myc epitope (red).  Scale
bar = 10 micrometers.  C.  Quantitation of mitochondrial morphology in Mfn-null cells
expressing wild-type and mutant Mfn1-Myc.  At least 150 cells were scored for each
infection; morphology was scored blind.
Figure 2-2.  Structure-function analysis of Mfn2.  A.  Domain structure of Mfn2, as in
Fig. 1, with mutations indicated.  B.  Representative images of Mfn2-Myc constructs
expressed in Mfn-null cells.  C.  Quantitation of mitochondrial morphology in Mfn-null
cells expressing wild-type and mutant Mfn2-Myc.  At least 150 cells scored, blind.
Figure 2-3.  Co-immunoprecipitation of full-length Mfn1 mutants.  Myc- and HA-tagged
Mfn1 point mutants were co-transfected in 293T cells.  Anti-Myc immunoprecipitates
(labeled Myc IP) and post-nuclear lysates (labeled lysate) were analyzed by Western blot
with anti-Myc (9E10) and anti-HA (HA.11) antibodies.  The relative load of
immunoprecipitates was 14 times that of lysates.  The positions of molecular weight
markers (in kDa) are indicated.
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Figure 2-4.  Mitofusin N-N and N-C domain interactions.  Co-immunoprecipitation as
described in Fig 3.  A.  Mfn1 N-terminal construct (1N), residues 1-579.  Mfn2 N-
terminal construct (2N), residues 1-598.  B.  Mfn1 C-terminal construct (1C), residues
629-741.  Mfn2 C-terminal construct (2C), residues 648-758.  N-terminal constructs as in
A.
Figure 2-5.  Characterization of Mfn1 N-C interaction.  Co-immunoprecipitation as
described in Fig 3.  A.  Mfn1 C-terminal construct (C-Myc, residues 629-741), wild-type
(wt) or L705P, co-immunoprecipitations with Mfn1 full length (full length-HA, residues
1-741), wild-type and L705P.  B. C-Myc co-immunoprecipitations with Mfn1 N-terminal
constructs (N-fragment-HA) of indicated residues.  Construct 1-579 includes the full N-
terminus until the TM domain; construct 1-453 includes the GTPase and HR1 domains;
construct 1-330 includes only the GTPase domain.  C.  C-Myc co-immunoprecipitations
with Mfn1 N-terminal construct (1-453-HA) with point mutations as indicated.
Figure 2-6.  Characterization of non-HR N-C interaction.  A.  Alignment of Mfn1 C-
terminal region between TM and HR2.  Non-conserved residues are highlighted in black.
Conserved charged mutations at indicated positions are boxed.  B.  Co-
immunoprecipitations as described in Fig. 3 between Mfn1 C-terminal constructs (Mfn1
C-Myc) of indicated residues and Mfn1 GTPase domain (Mfn1 1-330-HA).  C.  Co-
immunoprecipitations between Mfn1 C-terminal construct (Mfn1 629-741-Myc) and
Mfn1 GTPase domain.  D and F.  Quantitation of mitochondrial morphology in Mfn-null
cells (D) and wild-type cells (F) expressing full-length Mfn1-7xMyc with charge point
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mutations.  E and G.  Representative image of an Mfn-null cell (E) and wild-type cell (G)
expressing Mfn1 K643A 7xMyc.  Immunofluorescence as described in Fig 1, 2.  Scale
bar = 10 micrometers.
Figure 2-7. Mfn2 CMT2A disease mutations disrupt N-C interaction.  Co-
immunoprecipitations as described in Fig 3.  A.  Mfn2 C-terminal constructs (Mfn2 C-
Myc, residues 648-758) co-immunoprecipitations with Mfn2 N-terminal constructs
(Mfn2 N-HA, residues 1-598).  Constructs are wild-type (wt) or contain a designed
GTPase mutation (K109A) or CMT2A point mutations as indicated.  B.  Mfn1 C-
terminal construct (Mfn1 C-Myc, residues 629-741) co-immunoprecipitations with Mfn 2
N-HA constructs.
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Figure 2-2
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Chapter 3
Complementation Between Mouse Mfn1 and Mfn2 Protects Mitochondrial Fusion
Defects Caused by CMT2A Disease Mutations
Scott A. Detmer and David C. Chan
This chapter has been published in the Journal of Cell Biology (2007) 176: 405-414.
79
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
IO
L
O
G
Y
JCB: ARTICLE
© The Rockefeller University Press  $15.00
The Journal of Cell Biology, Vol. 176, No. 4, February 12, 2007 405–414
http://www.jcb.org/cgi/doi/10.1083/jcb.200611080 JCB 405
Introduction
Mitofusins are mitochondrial outer membrane GTPases required 
for mitochondrial fusion (Chan, 2006). Although yeast have one 
mitofusin, Fzo1 (Okamoto and Shaw, 2005), mammals contain 
two mitofusins, Mfn1 and Mfn2 (Santel and Fuller, 2001; Rojo 
et al., 2002; Chen et al., 2003). In the absence of either Mfn1 or 
Mfn2, cells have greatly reduced levels of mitochondrial fusion, 
and the imbalance of fusion and ! ssion events leads to mito-
chondrial fragmentation (Chen et al., 2003). In the absence 
of both Mfn1 and Mfn2, no mitochondrial fusion can occur, 
leading to severe mitochondrial and cellular dysfunction 
(Chen et al., 2005). Moreover, mitochondrial dynamics play an 
 important role in apoptosis (Youle and Karbowski, 2005), and 
maintenance of mitochondrial fusion has been linked to protection 
against apoptosis (Olichon et al., 2003; Sugioka et al., 2004; 
Neuspiel et al., 2005).
Mutations in Mfn2 cause Charcot-Marie-Tooth disease 
(CMT) type 2A, an autosomal dominant peripheral neuropathy 
(Zuchner et al., 2004). Most types of CMT disease involve 
Schwann cell dysfunction, resulting in the demyelination of 
peripheral nerves. However, CMT2A is an axonal form in 
which the axons of the longest sensory and motor nerves are 
selectively affected (Zuchner and Vance, 2005). There is cur-
rently no effective treatment for this disease. Interestingly, 
 another neurodegenerative disease, dominant optic atrophy, is 
caused by mutations in OPA1 (Alexander et al., 2000; Delettre 
et al., 2000), a mitochondrial intermembrane space protein that 
is also necessary for mitochondrial fusion. The sensitivity of 
neurons to mutations in Mfn2 and OPA1 suggests that such 
cells are particularly dependent on mitochondrial dynamics, 
which likely impacts the recruitment of mitochondria to 
 extended neuronal processes (Chen and Chan, 2006). Indeed, the 
disruption of mitochondrial dynamics has been experimentally 
linked to neuronal dysfunction (Stowers et al., 2002; Li et al., 
2004; Guo et al., 2005; Verstreken et al., 2005).
Several issues regarding mitofusin function and its rela-
tion to neurodegenerative disease remain poorly understood. 
First, it is unclear to what extent there is functional interplay 
between Mfn1 and Mfn2 during mitochondrial fusion. In 
 experiments with Mfn1- or Mfn2-null cells, either mitofusin 
can functionally replace the other, indicating functional 
redun dancy (Chen et al., 2003, 2005). However, some studies 
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sug gest distinct pathways or mechanisms for Mfn1 versus Mfn2 
(Cipolat et al., 2004; Ishihara et al., 2004). OPA1 action has 
been reported to depend on Mfn1 but not Mfn2 (Cipolat et al., 
2004). An in vitro study indicates that overexpressed Mfn1 is 
more effective than Mfn2 in tethering mitochondria, an effect 
that is correlated with a higher rate of GTP hydrolysis for Mfn1 
(Ishihara et al., 2004). Second, Mfn1 and Mfn2 have been 
shown to physically associate with each other (Chen et al., 
2003; Eura et al., 2003), but the functional signi! cance of such 
heterooligomeric complexes is poorly understood. Finally, it is 
unknown why Mfn2 mutations in CMT2A cause such highly 
cell type–speci! c defects. Patients with CMT2A show de! cits 
in the longest sensory and motor peripheral nerves, with a sub-
set showing additional degeneration in the optic nerve (Zuchner 
and Vance, 2005). The length-dependent degeneration of 
 peripheral nerves likely re" ects an inherent challenge of neu-
rons to supply functional mitochondria to the nerve terminals, 
but it remains unclear why primarily the peripheral and optic 
nerves are affected.
In this study, we have analyzed Mfn2 disease alleles that 
cause CMT2A. We ! nd that most of these mutants are not func-
tional for fusion when allowed to form only homotypic com-
plexes. However, these Mfn2 mutants can be complemented 
through the formation of heterotypic complexes with wild-type 
Mfn1. These results emphasize the close interplay between 
Mfn1 and Mfn2 in the mitochondrial fusion reaction, demon-
strate the functional importance of Mfn1–Mfn2 heterooligo-
meric complexes, and provide insights into the pathogenesis of 
Mfn2-dependent neuropathy.
Results
Many Mfn2 CMT2A alleles fail to rescue 
mitochondrial morphology in double 
Mfn-null cells
We have previously generated mouse embryonic ! broblast 
(MEF) cell lines with null mutations in both Mfn1 and Mfn2 
(double Mfn-null cells; Koshiba et al., 2004; Chen et al., 2005). 
These cell lines enable straightforward structure-function anal-
ysis of mouse mitofusins. Human and mouse Mfn2 are 95% 
identical, and all of the residues that were found mutated in the 
original CMT2A study (Zuchner et al., 2004) are conserved in 
mouse Mfn2. In the present study, we introduced nine of the 
originally reported point mutations into mouse Mfn2; these in-
clude mutations occurring immediately before the GTPase domain 
(V69F and L76P), within the GTPase domain (R94Q, R94W, 
Figure 1. Functional analysis of Mfn2 CMT2A alleles. 
(A) Domain structure of Mfn2 with the GTPase, hydrophobic hep-
tad repeat (HR), and transmembrane regions (TM) indicated. 
A sequence alignment of human Mfn2 with mouse Mfn2 and 
Mfn1 is shown for the regions surrounding CMT2A point 
 mutations. Note that the residues mutated in CMT2A disease are 
conserved between human and mouse Mfn2. The horizontal 
gray bar indicates the GTPase G1 motif. (B) Representative 
images of double Mfn-null cells expressing myc-tagged Mfn2 
at a low multiplicity of infection. Mitochondria are visualized 
by matrix-targeted EGFP (green), and Mfn2-expressing cells 
are identifi ed by immunofl uorescence against the myc epitope 
(red). Note mitochondrial aggregation induced by the CMT2A 
allele L76P. Bar, 10 μm. (C) Summary of mitochondrial pro-
fi les when Mfn2 CMT2A alleles are expressed in wild-type 
MEFs (left two columns) and double Mfn-null MEFs (right two 
columns). In each case, infected cells were scored for mito-
chondrial morphology, and the three categories of tubular mito-
chondria (Fig. S1, A and B; available at http://www.jcb.org/
cgi/content/full/jcb.200611080/DC1) were added to yield 
the percentage of cells with tubular mitochondria. Mitochon-
drial aggregation was independently scored. More than 
150 cells were scored for each experiment. As additional ref-
erence points, using the same scoring criteria, we fi nd that 
0% of Mfn1-null cells and 10% of Mfn2-null cells have tubular 
mitochondria (see controls in Fig. 6, C and D). 
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T105M, P251A, R274Q, and R280H), and in a C-terminal heptad 
repeat region (W740S; Fig. 1 A). By expressing these disease 
alleles in wild-type and double Mfn-null MEFs, we could 
 assess their subcellular localization, effects on mitochondrial 
morphology, and ability to mediate mitochondrial fusion.
Mock-infected wild-type MEFs have a range of mito-
chondrial pro! les, but the vast majority of cells show consider-
able amounts of tubular mitochondria (Fig. 1 C and Fig. S1 A, 
available at http://www.jcb.org/cgi/content/full/jcb.200611080/
DC1). The expression of wild-type Mfn2 or the GTPase mutant 
Mfn2K109A by retroviral transduction did not affect mitochon-
drial morphology. We found that all of the CMT2A mutants 
properly localized to mitochondria as determined by immuno-
" uorescence. However, seven of the nine CMT2A alleles (all 
except Mfn2V69F and Mfn2R274Q) caused substantial mitochon-
drial aggregation when cells were infected at a high multiplicity 
of infection (Fig. S2). At low infection rates, most infected cells 
have only one proviral copy and express about fourfold Mfn2 
compared with endogenous Mfn2 in wild-type cells (Fig. S3). 
Under these conditions, only Mfn2L76P, Mfn2T105M, and 
 Mfn2W740S caused high levels of mitochondrial aggregation 
(Fig. 1 C). In contrast, such mitochondrial aggregation was not 
found in cells expressing wild-type Mfn2 and was found only in 
a few cells expressing Mfn2K109A. This mitochondrial aggregation 
phenotype may re" ect the aberration of Mfn2 function by 
CMT2A mutations; however, the effect is clearly dosage depen-
dent and is not observed at physiological expression levels (see 
Fig. 4). Therefore, its relevance to CMT2A disease remains to 
be determined.
To evaluate the Mfn2 CMT2A alleles for mitochondrial 
fusion activity, we expressed them in double Mfn-null cells. 
Cells lacking mitofusins are fully de! cient for mitochondrial 
fusion and show completely fragmented mitochondrial mor-
phology (Chen et al., 2005). The expression of wild-type Mfn2 
restored mitochondrial fusion, resulting in tubular mitochon-
drial morphology (Fig. 1, B and C; and Fig. S1 B). In contrast, 
the GTPase mutant Mfn2K109A behaved as a complete loss of 
function allele, showing no ability to restore mitochondrial 
 tubules. The CMT2A mutants Mfn2R94Q, Mfn2R94W, Mfn2T105M, 
Mfn2P251A, and Mfn2R280H are similarly unable to promote mito-
chondrial tubules in double Mfn-null cells. In contrast, cells 
 expressing Mfn2V69F, Mfn2L76P, Mfn2R274Q, or Mfn2W740S showed 
a considerable restoration of mitochondrial tubules. Therefore, 
more than half of the CMT2A mutants are nonfunctional.
Nonrescuing CMT2A alleles lack 
mitochondrial fusion activity
To de! nitively evaluate the fusion activity of CMT2A alleles, 
we tested them in a polyethylene glycol (PEG) mitochondrial 
fusion assay. In this assay, double Mfn-null cells containing 
 either mitochondrially targeted EGFP or mito-DsRed were each 
infected with retrovirus expressing a CMT2A allele. Hybrids 
between the two cell lines were scored for mitochondrial fusion. 
Cell hybrids that formed between double Mfn-null cells or cells 
expressing Mfn2K109A never showed mitochondrial fusion (Fig. 2). 
In contrast, the expression of wild-type Mfn2 resulted in 
 extensive mitochondrial fusion: 75% of the cell hybrids exhibited 
a complete overlay of EGFP and DsRed (scored as full fusion) 
or a nearly complete overlay with some singly labeled mito-
chondria remaining (scored as extensive fusion). 20% of these 
hybrids had no colabeled mitochondria (scored as no fusion) 
and invariably had fragmented mitochondria. These hybrids 
likely arose from uninfected cells. When clonal infected cell 
lines were used (Koshiba et al., 2004), all cell hybrids showed 
extensive mitochondrial fusion.
We found excellent agreement between the ability of a 
CMT2A allele to restore mitochondrial tubules to double Mfn-
null cells and their fusion activity in the PEG assay. The Mfn2 
CMT2A alleles Mfn2V69F, Mfn2L76P, Mfn2R274Q, and Mfn2W740S 
induced " uorophore mixing as ef! ciently as wild-type Mfn2, 
indicating that they are highly functional. In contrast, mutants 
Mfn2R94Q, Mfn2R94W, Mfn2T105M, Mfn2P251A, and Mfn2R280H were 
all completely de! cient for mitochondrial fusion. Interestingly, 
the ! ve nonfunctional alleles are all in positions that are 
Figure 2. Lack of mitochondrial fusion activity in many 
CMT2A alleles. Double Mfn-null cells expressing either mito-
DsRed or mito-EFGP were infected with the same Mfn2 construct. 
The PEG fusion assay was used to evaluate mitochondrial 
 fusion activity in cell hybrids formed from such cells. (A) Rep-
resentative merged images of cell hybrids. No fusion is 
 detected with mock-, Mfn2K109A-, or Mfn2R94Q-infected cells. 
Extensive fusion is observed with wild-type Mfn2 and 
 Mfn2L76P. Bar, 10 μm. (B) Quantitation of mitochondrial 
 fusion in cell hybrids. More than 200 cell hybrids were 
scored per experiment.
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 conserved between Mfn1 and Mfn2. Three of the four func-
tional alleles are in nonconserved positions.
Endogenous Mfn1 functionally complements 
the CMT2A mutant Mfn2R94Q to induce 
mitochondrial fusion
Our PEG fusion assays showed that Mfn2R94Q, along with four 
other CMT2A alleles, has no mitochondrial fusion activity in 
double Mfn-null cells. This allele is particularly interesting 
 because position 94 is the most commonly mutated residue found 
in CMT2A. Multiple clinical studies have found familial or de 
novo mutations of residue 94 to either Q or W (Zuchner et al., 
2004, 2006; Kijima et al., 2005; Chung et al., 2006; Verhoeven 
et al., 2006). To de! nitively study the in vivo properties of this 
allele, we used homologous recombination to place the R94Q 
mutation into the endogenous mouse Mfn2 locus in embryonic 
stem (ES) cells (Fig. 3, A–D). For positive selection, the tar-
geting construct contained a neomycin expression cassette 
" anked by loxP sites. After the generation of mice containing 
the knockin allele, Cre-mediated recombination was used to 
excise the neomycin cassette in vivo, resulting in an MFN2 
 locus containing the R94Q mutation and a short loxP scar located 
in the adjacent intron (Fig. 3, A and D). We mated mice hetero-
zygous for the Mfn2R94Q allele, and homozygous embryos were 
used to derive Mfn2R94Q homozygous MEF cell lines.
Our molecular analyses indicate that these cell lines ex-
press no wild-type Mfn2 while expressing endogenous levels of 
Mfn2R94Q (Fig. 3, E and F). To con! rm the expression of 
 Mfn2R94Q in these cell lines, we used RT-PCR to analyze Mfn2 
RNA transcripts. We ampli! ed exon 5 (which encodes residue 
94) and the adjoining sequences of Mfn2 cDNA by PCR. The 
presence of the R94Q mutation within the ampli! ed cDNA frag-
ment was diagnosed by digestion with the restriction  enzyme 
MspA1I, which cuts uniquely at a site introduced by the R94Q 
mutation. As expected, the cDNA fragment was ampli! ed from 
cDNA of wild-type and Mfn2R94Q homozygous cells but not 
Mfn2-null cells (Fig. 3 E). The cDNA from wild-type cells is 
completely resistant to MspA1I digestion, whereas the cDNA 
from Mfn2R94Q homozygous cells was completely digested by 
MspA1I, demonstrating that all Mfn2 transcripts contain the R94Q 
mutation. Having con! rmed mRNA expression of the mutant 
 allele, we next con! rmed protein expression. Immunoblot analysis 
indicated that endogenous levels of Mfn1 and Mfn2 are present in 
wild-type and Mfn2R94Q homozygous cell lines (Fig. 3 F).
Given that Mfn2R94Q has no fusion activity in double Mfn-
null cells (Figs. 1 and 2), we expected Mfn2R94Q homozygous cells 
to have fragmented mitochondria similar to those found in Mfn2-
null cells (Chen et al., 2003, 2005). Surprisingly, the scoring of 
 mitochondrial pro! les indicated that most Mfn2R94Q homozygous 
cells have predominantly tubular mitochondria; this is in striking 
contrast to Mfn2-null cells, which have extensive mitochondrial 
fragmentation (Fig. 4, A and B). In addition, we did not ! nd any 
mitochondrial aggregation in the Mfn2R94Q homozygous cell line.
Therefore, although Mfn2R94Q behaves as a null allele 
when expressed in double Mfn-null cells, it is clearly highly 
functional in our homozygous knockin cells. In evaluating 
these results, it is important to consider the total complement 
Figure 3. Construction of MEFs containing homozygous Mfn2R94Q knockin 
mutations. (A) Schematic of Mfn2 targeting construct and strategy. A portion 
of the Mfn2 genomic locus containing exons 4–6 is shown on top based 
on Ensembl transcript ID ENSMUST00000030884 (www.ensembl.org). 
The knockin targeting vector below contains the R94Q mutation (*) 
placed in exon 5 as well as a fl oxed neomycin cassette for positive selec-
tion and a diphtheria toxin cassette (DTA) for negative selection. Homo-
logous recombination in ES cells leads to the confi guration in the third line, 
which can be detected by PCR using the A and B pairs of primers (trian-
gles), as shown in B and C. Mice were generated with the targeted ES 
cells, and Cre recombination in vivo was used to excise the neomycin cas-
sette, leading to the bottom confi guration containing the R94Q mutation 
and loxP scar (arrowhead). (B) PCR screen of ES cells using primer set A 
for detection of the correct targeting of the left arm. Four ES cell clones are 
shown; the fi rst two clones are positive. Because the 5′ primer is outside the 
targeting construct, only correctly targeted clones will yield the desired PCR 
product. (C) PCR screen of ES cells using primer set B for detection of the 
correct targeting of the right arm. The same two ES cell clones are positive. 
Note that the 3′ primer is outside the targeting construct. (D) PCR screen of 
Mfn2 genomic structure after in vivo Cre-mediated excision of the PGK-
 neomycin cassette. Excision leaves behind a 140-bp loxP scar as dia-
grammed. Three sets of PCR reactions were used to confi rm the presence 
of the loxP scar in Mfn2R94Q homozygous MEFs (lane 2) but not wild-type 
MEFs (lane 1). (E) Genotype assay for Mfn2 transcripts. The schematic on 
top shows the genomic Mfn2 locus containing exons 4–6. Exon 5 encodes 
residue 94. A cDNA fragment was amplifi ed using the indicated primers 
in exons 4 and 6. cDNA amplifi cation and restriction digestion was per-
formed on fi rst-strand cDNA from wild-type (+/+), Mfn2R94Q–Mfn2R94Q, 
and Mfn2-null cells. In the Mfn2R94Q cDNA, the engineered R94Q mutation 
(*) introduces an MspA1I site, resulting in cleavage of the 233-bp PCR 
product into 146- and 87-bp fragments. (F) Expression of Mfn1 and the 
Mfn2R94Q allele at endogenous levels. Postnuclear whole cell lysates from 
the  indicated MEFs were separated by SDS-PAGE and immunoblotted 
with an anti-Mfn2 (top) or Mfn1 antibody (middle). β-actin was used as a 
loading control (bottom).
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of mitofusins in each cellular context because Mfn1 and Mfn2 
can form both homooligomeric (Mfn1–Mfn1 or Mfn2–Mfn2) 
and heterooligomeric (Mfn1–Mfn2) complexes (Chen et al., 
2003; Eura et al., 2003). When Mfn2R94Q is expressed in dou-
ble Mfn-null cells, only Mfn2R94Q–Mfn2R94Q homooligomeric 
complexes can be formed, and such complexes are clearly 
 inactive for mitochondrial fusion. In Mfn2R94Q homozygous 
knockin cells, endogenous Mfn1 is still present (Fig. 3 F). 
Therefore, three possible complexes can be formed: Mfn1–
Mfn1, Mfn1–Mfn2R94Q, and Mfn2R94Q–Mfn2R94Q (Fig. 4 A). 
The phenotype of Mfn2-null cells (which contain only Mfn1–
Mfn1 homooligomeric complexes) indicates that endogenous 
levels of Mfn1–Mfn1 complexes alone are not suf! cient to 
promote tubular mitochondria. Given that Mfn2R94Q–Mfn2R94Q 
complexes are nonfunctional (Fig. 2), these results strongly 
suggest that Mfn2R94Q can cooperate with Mfn1 to form 
Mfn1–Mfn2R94Q complexes capable of promoting fusion.
Mfn2 CMT2A mutants physically associate 
with wild-type Mfn1 and Mfn2
If this model of complementation is correct, Mfn2R94Q should 
be able to physically associate with wild-type Mfn1. We tested 
whether the Mfn2 CMT2A mutants could coimmunoprecipi-
tate with wild-type Mfn1 and Mfn2. In MEFs, all of the Mfn2 
CMT2A mutants associated with Mfn1 at normal levels with 
the exception of Mfn2T105M, which showed lower levels (Fig. 
5 A). Similarly, the Mfn2 CMT2A mutants associated with 
Mfn2, although at slightly reduced levels compared with wild-
type Mfn2. Again, Mfn2T105M had low binding. It should be 
noted that when analogous immunoprecipitation experiments 
were performed in transfected 293T cells, the reduction in 
 Mfn2T105M binding was subtle (unpublished data). Therefore, 
although Mfn2T105M has reduced binding to wild-type Mfn1 
and Mfn2, this defect is not observed at high expression levels. 
The engineered GTPase mutant Mfn2K109A, which interacted 
strongly with Mfn1, interacted poorly with Mfn2. These results 
suggest that the mutant Mfn2 molecules can interact with 
wild-type Mfn1 and Mfn2 and can potentially participate in or 
modify the fusion reaction.
Mfn1 but not Mfn2 complements CMT2A 
alleles to induce mitochondrial fusion
To learn more about the complementation of Mfn1 and  Mfn2R94Q 
and whether this is a unique property of the Mfn2R94Q allele, 
we tested all of the nonfunctional Mfn2 CMT2A alleles for 
complementation with wild-type Mfn1 and Mfn2. We expressed 
alleles Mfn2R94Q, Mfn2R94W, Mfn2T105M, Mfn2P251A, and Mfn2R280H 
in either Mfn2- or Mfn1-null cells and scored mitochondrial 
pro! les. Most Mfn2-null cells have fragmented  mitochondrial 
morphology, with only %13% of the cells having short mito-
chondrial tubules. The expression of wild-type Mfn2 in these 
cells restores normal tubular mitochondrial morphology 
(Fig. 6, A and C). Remarkably, the expression of each of the ! ve 
CMT2A alleles into Mfn2-null cells resulted in extensive mito-
chondrial tubulation. The GTPase mutant Mfn2K109A was also 
able to induce mitochondrial tubulation, although its effect was 
considerably weaker than that of the CMT2A alleles. Because 
Mfn2-null cells contain Mfn1, the expression of CMT2A alleles 
in Mfn2-null cells results in the formation of three possible 
complexes: Mfn1–Mfn1, Mfn1–Mfn2CMT2A, and Mfn2CMT2A–
Mfn2CMT2A (Fig. 6 A). These results strongly support and 
 generalize our interpretation of the Mfn2R94Q homozygous 
Figure 4. Tubular mitochondria in Mfn2R94Q–Mfn2R94Q cells. (A) Represent-
ative images of mitochondrial morphology in wild-type (+/+), Mfn2R94Q–
Mfn2R94Q, and Mfn2-null (−/−) cells. Mitochondria were visualized by 
MitoTracker red staining. Below each cell, the potential mitofusin oligomers 
are listed. Bar, 10 μm. (B) Quantitation of mitochondrial morphology. For 
each cell line, 100 cells were scored in three independent experiments. 
 Error bars indicate SD.
Figure 5. Physical association of mutant Mfn2 with 
wild-type Mfn1 and Mfn2. (A) Myc-tagged Mfn2 
mutants were expressed in double Mfn-null cell lines 
stably expressing HA-tagged Mfn1. Anti-myc immuno-
precipitates (myc IP) and postnuclear lysates (lysate) 
were analyzed by Western blotting with anti-myc 
and anti-HA antibodies. Mock (−) or Drp1-myc–
 infected cells were used as negative controls. The 
relative load of the immunoprecipitates was 14 
times that of the lysates. (B) Same as in A except 
performed in double Mfn-null cell lines stably 
 expressing HA-tagged Mfn2. Positions of the Mfn2-
myc and Drp1-myc bands and positions of molecular 
mass markers (given in kilodaltons) are indicated.
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knockin cell line: Mfn2 disease alleles can cooperate with Mfn1 
to promote fusion activity. This activity is likely mediated 
by Mfn1–Mfn2CMT2A heterooligomers. Because even mutant 
 Mfn2K109A shows a low level of complementation with Mfn1, 
Mfn2 need not have GTPase activity to cooperate with Mfn1.
In contrast, the expression of mutants Mfn2R94Q, Mfn2R94W, 
Mfn2T105M, Mfn2P251A, and Mfn2R280H in Mfn1-null cells did not 
induce tubulation (Fig. 6, B and D). Mfn1-null cells expressing 
these alleles had extensively fragmented mitochondria. In this 
experiment, only Mfn2 complexes can be formed: Mfn2–Mfn2, 
Mfn2CMT2A–Mfn2CMT2A, and Mfn2–Mfn2CMT2A (Fig. 6 B). 
Therefore, in contrast to Mfn1–Mfn2CMT2A complexes, Mfn2–
Mfn2CMT2A complexes do not appear to be competent for fusion.
Complementation between mutant 
Mfn2 and Mfn1 in trans
The aforementioned experiments demonstrate that Mfn1 can 
complement Mfn2 CMT2A alleles. By the nature of the experi-
ment, it is impossible to know whether the complementation is 
occurring on the same mitochondria (in cis), between adjacent 
mitochondria (in trans), or both. To test whether the nonfunc-
tional Mfn2 mutants can support fusion with wild-type mito-
chondria in trans, we returned to the PEG cell hybrid assay for 
mitochondrial fusion. In this assay, mitochondria from double 
Mfn-null cells cannot fuse with mitochondria from wild-type 
cells, indicating a requirement for mitofusins on adjacent mito-
chondria (Koshiba et al., 2004; Chen et al., 2005). We expressed 
Mfn2 alleles in double Mfn-null cells and assessed mitochon-
drial fusion in cell hybrids with wild-type cells. In this experi-
mental scheme, Mfn2CMT2A–Mfn2CMT2A complexes present on 
one set of mitochondria are tested for fusion with mitochondria 
containing a full complement of wild-type mitofusin complexes 
(Mfn1–Mfn1, Mfn2–Mfn2, and Mfn1–Mfn2 complexes). As 
expected, when double Mfn-null cells expressing wild-type 
Mfn2 were fused with wild-type cells, we found extensive co-
labeling of mitochondria (Fig. 7 B). Moreover, the Mfn2 CMT2A 
alleles Mfn2R94Q, Mfn2R94W, Mfn2P251A, and Mfn2R280H induce 
readily detectable but moderate levels of fusion that are lower 
than those of wild-type Mfn2 but are much more than those of 
Mfn2K109A (Fig. 7, A and B). However, the Mfn2T105M allele 
 allows essentially no mitochondrial fusion. These results indicate 
that most Mfn2 CMT2A mutants can function in trans with 
wild-type mitofusin complexes.
To determine whether this complementation is caused by 
interactions with wild-type Mfn1–Mfn1 or Mfn2–Mfn2 
 complexes, we next tested the Mfn2 CMT2A alleles in mito-
chondrial fusion assays with Mfn2-null and Mfn1-null cells. 
Mfn2 mutants Mfn2R94Q, Mfn2R94W, Mfn2P251A, and Mfn2R280H 
Figure 6. Mfn1 but not Mfn2 complements Mfn2 CMT2A 
 alleles. (A and B) Representative images of mitochondrial 
morphology in Mfn2-null (A) or Mfn1-null MEFs (B) expressing 
myc-tagged Mfn2 alleles. Mitochondria are visualized by 
 mitochondrially targeted EGFP (green), and the infected cells 
are detected by anti-myc immunofl uorescence (red). Note that 
Mfn2R94Q promotes tubulation in Mfn2-null but not Mfn1-null 
MEFs. The potential mitofusin complexes in each experiment 
are listed on the right, with the CMT2A mutant molecule indi-
cated by Mfn2*. Bars, 10 μm. (C and D) Quantitation of 
 mitochondrial morphology in Mfn2- (C) and Mfn1-null MEFs (D) 
expressing Mfn2 CMT2A alleles. In Mfn1-null MEFs, very 
short mitochondrial tubules were scored as fragmented. 150 
cells were scored in two independent experiments. Error bars 
indicate SD.
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promoted moderate levels of mitochondrial fusion in cell 
 hybrids with Mfn2-null cells (Fig. 7, A and C). In contrast, the 
same mutants induced no mitochondrial fusion in hybrids with 
Mfn1-null cells (Fig. 7, A and D). These results demonstrate 
that most Mfn2CMT2A alleles can promote fusion when exposed 
to membranes containing Mfn1 but not Mfn2. As expected from 
its failure to promote fusion with wild-type mitochondria, 
Mfn2T105M showed no fusion activity with either the Mfn2- or 
Mfn1-null cells.
Discussion
The Mfn1–Mfn2 heterooligomeric 
complex is an important regulator 
of mitochondrial dynamics
Previous immunoprecipitation studies indicated that Mfn1 and 
Mfn2 form heterooligomeric complexes (Chen et al., 2003; Eura 
et al., 2003). However, most functional studies have focused on 
Mfn1 or Mfn2 in isolation, and, therefore, we have little infor-
mation on the functional importance of the heterooligomeric 
complex. The only direct demonstration that this complex is 
functional comes from the observation that cell hybrids between 
Mfn1- and Mfn2-null cells show low levels of mitochondrial 
 fusion, suggesting that Mfn1–Mfn2 heterotypic complexes formed 
in trans have fusion activities that are roughly comparable with 
homooligomeric Mfn1 or Mfn2 complexes alone (Chen et al., 
2005). Our current study of Mfn2 disease alleles reveals an inti-
mate interplay between Mfn1 and Mfn2 in mediating mitochon-
drial fusion. A subset of Mfn2 disease alleles lack mitochondrial 
fusion activity in isolation but show substantial fusion activity in 
the presence of Mfn1. In addition, PEG fusion assays (Fig. 7) 
indicate that this cooperation between Mfn1 and mutant Mfn2 at 
least partially occurs through interactions in trans. Such close 
physical and functional interactions between Mfn1 and Mfn2 
support the view that they have similar biochemical functions 
during mitochondrial membrane fusion. These results highlight 
the importance of heterooligomeric Mfn1–Mfn2 complexes in 
the control of mitochondrial dynamics.
Our study greatly extends a different type of complemen-
tation demonstrated in the yeast mitofusin Fzo1p. Fzo1p dem-
onstrates strong complementation between speci! c pairs of null 
alleles, resulting in the restoration of mitochondrial tubules 
(Grif! n and Chan, 2006). For example, an fzo1 mutant contain-
ing a GTPase mutation can cooperate with an fzo1 mutant con-
taining a heptad repeat mutation to promote mitochondrial 
fusion. Such complementation re" ects the oligomeric nature of 
mitofusin complexes and indicates that each subunit of the 
oligomer need not be fully functional to provide function to the 
complex. However, this previous study (Grif! n and Chan, 2006) 
was limited to Fzo1 homooligomeric complexes, unlike the het-
erooligomeric complexes studied here. Indeed, we have not 
been able to demonstrate a similar type of complementation in 
Mfn1 or Mfn2 homooligomeric complexes (unpublished data).
Functional heterogeneity of CMT2A alleles
Our results reveal some functional heterogeneity in Mfn2 
 mutants that underlie CMT2A disease. The Mfn2T105M allele 
Figure 7. Mfn1 complements Mfn2 CMT2A mutants in trans. (A) Double 
Mfn-null MEFs expressing mitochondrial DsRed and Mfn2R94Q were fused 
to wild-type cells (left), Mfn2-null cells (middle), or Mfn1-null cells (right). As 
indicated by the green circles, the latter three cell lines expressed mitochon-
drial EGFP. For each cell line, all potential mitofusin oligomers are listed 
under the horizontal line. Colabeled mitochondrial tubules (indicated with 
arrows) are clearly observed in cell hybrids with wild-type and Mfn2-null 
cells but not with Mfn1-null cells. Bar, 10 μm. (B–D) Double Mfn-null cells 
expressing the indicated Mfn2 mutant were assayed for mitochondrial 
 fusion in cell hybrids with wild-type cells (B), Mfn2-null cells (C), and Mfn1-
null cells (D). For each PEG fusion assay, at least 200 cell hybrids 
were scored.
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behaved somewhat differently from the other nonfunctional 
 alleles. Mfn2T105M, like the other nonfunctional alleles, could be 
complemented by wild-type Mfn1. However, it showed reduced 
physical interactions with Mfn1 and did not show complemen-
tation with Mfn1 in trans. Presumably, Mfn2T105M can be com-
plemented by Mfn1 in cis but not in trans.
Over half of the CMT2A alleles are nonfunctional in dou-
ble Mfn-null cells, but the rest show substantial fusion activity. 
More sensitive assays will be necessary to understand how the 
functional alleles affect mitochondrial dynamics. Some of the 
functional alleles caused severe mitochondrial aggregation 
when overexpressed. Future studies will determine the physio-
logical signi! cance of this phenotype.
Implications for pathogenesis 
and treatment of CMT2A
Our results have important implications for understanding the 
pathogenesis of CMT2A, especially because four of the ! ve 
nonfunctional mutant alleles described in this study (Mfn2R94Q, 
Mfn2R94W, Mfn2T105M, and Mfn2R280H) are among the most com-
monly identi! ed Mfn2 mutations (Zuchner et al., 2004, 2006; 
Kijima et al., 2005; Lawson et al., 2005; Chung et al., 2006; 
Verhoeven et al., 2006). In contrast to the broad expression pat-
tern of Mfn2, one of the remarkable features of CMT2A disease 
is its apparent cell type speci! city. In most patients, the clinical 
features are restricted to the motor and sensory neurons of the 
peripheral nervous system. In a subset of patients (designated as 
hereditary motor and sensory neuropathy type VI), the optic 
nerve is additionally affected (Zuchner et al., 2006). A recent 
study has suggested possible involvement of the central ner-
vous system (Chung et al., 2006). This clinical picture suggests 
that most cells in CMT2A patients likely have only mild pertur-
bations in mitochondrial dynamics. Moreover, in a typical 
patient, only the longest peripheral sensory and motor neurons 
are  affected. This length dependence suggests that even in 
the  peripheral nervous system, the defects in mitochondrial 
 dynamics are not catastrophic because only the neurons with the 
highest demands for precise control of mitochondrial fusion 
are damaged.
Our studies of the Mfn2R94Q knockin mice are ongoing, 
but initial observations support the conclusion that CMT2A dis-
ease results from a mild perturbation in mitochondrial  dynamics. 
Thus far, we have not observed a neurological phenotype in the 
heterozygous knockin mice. The lack of an obvious peripheral 
neuropathy in these mice may re" ect the fact that motor neurons 
in mice are much shorter than in humans, where their extreme 
length likely places more stringent requirements on the precise 
regulation of mitochondrial fusion. Although Mfn2-null ani-
mals die in utero, Mfn2R94Q homozygous animals are born live 
and die at %3 wk of age. The much milder phenotype of 
 Mfn2R94Q homozygous animals compared with Mfn2-null ani-
mals further supports our conclusion that Mfn2R94Q can be 
 partially complemented by endogenous Mfn1. Mfn2R94Q homo-
zygous animals have severe movement defects (unpublished data), 
and we are currently analyzing the basis for this phenotype.
In considering the effects of Mfn2 mutations, our results 
indicate that the full complement of mitofusins in any given cell 
type is the most relevant parameter in determining the dysfunc-
tion of mitochondrial fusion. This concept is clearly illustrated 
in our analysis of Mfn2 CMT2A mutations in MEFs. When 
 Mfn2R94Q is expressed in double Mfn-null cells, it is completely 
de! cient for fusion activity, indicating that homooligomeric 
Mfn2R94Q complexes are nonfunctional. In contrast, MEFs con-
taining homozygous Mfn2R94Q knockin mutations show only 
mild defects in mitochondrial morphology, a phenotype that is 
quite different from the extensive mitochondrial fragmentation 
observed in Mfn2-null MEFs. This observation indicates that in 
the presence of endogenous wild-type Mfn1, Mfn2R94Q is actu-
ally highly functional. By expressing Mfn2R94Q and other  mutant 
alleles in Mfn1-null versus Mfn2-null cells, we found that wild-
type Mfn1 but not Mfn2 can cooperate with mutant Mfn2 to 
promote mitochondrial fusion.
These results suggest that the widespread expression pat-
tern of Mfn1 (Rojo et al., 2002; Santel et al., 2003) protects 
 mitochondrial dynamics in most cells in CMT2A patients carrying 
nonfunctional alleles of Mfn2. CMT2A is an autosomal domi-
nant disease, with patients carrying one mutant and one wild-
type allele of Mfn2. In cell types that express Mfn1, Mfn1 
homooligomeric complexes would be normal, and Mfn1–Mfn2 
heterooligomeric complexes would also be largely normal as a 
result of the cooperation between Mfn1 and mutant Mfn2 (Fig. 8). 
For Mfn2 homooligomeric complexes, Mfn2wt–Mfn2wt com-
plexes would be functional, whereas Mfn2wt–Mfn2CMT2A and 
Mfn2CMT2A–Mfn2CMT2A complexes would be nonfunctional. 
Therefore, of the three classes of mitofusin complexes, only a 
subset of one class is nonfunctional, resulting in mild mitochon-
drial fusion defects in most cells. In cell types with low or no 
Mfn1 expression, the full complement of mitofusin complexes 
consists primarily of Mfn2 homotypic complexes. In relative 
terms, such cells would experience a severe loss of mito-
chondrial fusion because the majority of mitofusin com-
plexes (Mfn2wt–Mfn2CMT2A and Mfn2CMT2A–Mfn2CMT2A) lack 
mitochondrial fusion activity. Therefore, we propose that in 
CMT2A disease, the widespread expression pattern of Mfn1 
serves to protect  mitochondrial fusion in most cells through 
Figure 8. Mfn1 complements mutant Mfn2 to preserve mitochondrial 
 fusion in most CMT2A cells. (A) In most wild-type cell types, there are three 
classes of mitofusin complexes (I, II, and III) that maintain mitochondria in 
a highly dynamic state. (B) CMT2A patients are heterozygous for a mutant 
Mfn2 allele (designated Mfn2*). In most cells, defects in mitochondrial 
 dynamics are mild because only a subset of class III complexes are nonfunc-
tional (highlighted in black). In contrast, cells expressing little or no Mfn1 
would suffer a large decline in mitochondrial fusion activity. Such cells con-
tain only class III complexes, and the majority of these are nonfunctional.
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 heterooligomeric complex formation with mutant Mfn2. 
 Peripheral nerves may contain little or no Mfn1 expression to 
compensate for mutant Mfn2. The resulting defects in mito-
chondrial dynamics coupled with the extreme length of these 
neurons lead to neuronal dysfunction and axon degeneration.
Our results emphasize the close interplay between Mfn1 
and Mfn2 and the importance of the Mfn1–Mfn2 heterooligo-
mer complex in control of mitochondrial fusion. Finally, our 
results suggest that an important area of future study is the reg-
ulation of Mfn1 levels. Methods to increase Mfn1 expression 
in the peripheral nervous system may bene! t CMT2A patients 
by promoting the complementation of mitochondrial fusion.
Materials and methods
Cloning and retroviral transduction
The mitofusin 7xMyc and 3xHA constructs were described previously 
(Chen et al., 2003). The CMT2A point mutations were introduced to Mfn2-
7xMyc in pcDNA3.1 by PCR with primers encoding the mutations. After 
cloning, the entire amplifi ed region was verifi ed by sequencing. The  mutant 
cDNAs were then cloned into the retroviral construct pCLBW, and viral 
 supernatant was produced and collected as described previously (Chen 
et al., 2003).
Immunofl uorescence
Immunofl uorescence against Mfn2-7xMyc was performed as described 
previously (Chen et al., 2003). In brief, cells were grown on poly-L-lysine–
treated coverslips, fi xed in formalin, permeabilized with 0.1% Triton X-100 
in PBS, and blocked with 5% bovine calf serum in PBS. The 9E10 primary 
antibody was detected with a Cy3-labeled secondary antibody. Coverslips 
were mounted with GelMount and imaged with a plan NeoFluar 63× NA 
1.25 oil immersion objective (Carl Zeiss MicroImaging, Inc.) on a laser-
scanning confocal microscope (model 410; Carl Zeiss MicroImaging, 
Inc.). Images were acquired with LSM software (version 1; Carl Zeiss 
 MicroImaging, Inc.) and pseudocolored in Photoshop CS (Adobe). Mito-
chondria were visualized by mitochondrially targeted GFP or DsRed as 
previously described (Chen et al., 2005). In other cases, mitochondria 
were stained using 150 nM MitoTracker red CMXRos (Invitrogen) and post-
fi xed in acetone.
PEG fusion assay
PEG fusion assays were performed in the presence of cycloheximide as 
 described previously (Chen et al., 2003, 2005). Cell hybrids were fi xed 
7 h after PEG treatment. The mitochondrial GFP signal was enhanced 
by incubation with an anti-GFP antibody conjugated to AlexaFluor488 
(Invitrogen).
Derivation of Mfn2R94Q homozygous MEFs
The two arms of the targeting construct were derived from Mfn2 genomic 
sequence (129/SvJ background) and subcloned into the targeting vector 
pPGKneobpAlox2PGKDTA. Before subcloning of the left arm, the R94Q 
mutation was engineered into exon 5 by PCR. The targeting construct was 
verifi ed by DNA sequencing. The linearized targeting construct was elec-
troporated into low-passage 129/SvEv ES cells as described previously 
(Chen et al., 2003). Correctly targeted ES clones were identifi ed by PCR 
using the primer sets A and B depicted in Fig. 3 A. Chimeric mice were 
generated by the injection of ES cells into C57BL/6 blastocysts. After con-
fi rmation of germline transmission, the fl oxed neomycin cassette was 
 removed by mating the knockin mice with the EIIA-cre deletor line (Lakso 
et al., 1996). Heterozygous knockin animals were mated, and MEFs were 
derived from day 10.5 embryos as described previously (Chen et al., 
2003). Homozygous embryos were identifi ed by PCR genotyping of extra-
embryonic membranes. Wild-type, Mfn1-null, Mfn2-null, and Mfn2R94Q–
Mfn2R94Q MEFs were cultured in DME containing 10% bovine calf serum, 
1 mM L-glutamine, and penicillin/streptomycin. Double Mfn-null MEFs were 
cultured with 10% FCS in place of bovine calf serum.
RNA isolation and RT-PCR
MEFs were resuspended directly in 800 μl STAT-60 (IsoTex Diagnostics, 
Inc.), and RNA was isolated according to the manufacturer’s instructions. 
cDNA was generated by fi rst-strand synthesis on total RNA using oligo(dT) 
and Superscript II RT (Invitrogen). A cDNA fragment containing exon 5 was 
subsequently amplifi ed (primers 5′-G G G G C C T A C A T C C A A G A G A G -3′ 
and 5′-G C A G A A C T T T G T C C C A G A G C -3′). This product was digested 
overnight at 37°C with MspA1I.
MEF lysates
MEF cell lysates were prepared from confl uent 6-cm plates. For protein 
 lysates, cells were washed once with PBS and resuspended in 400 μl lysis 
buffer (150 mM NaCl, 50 mM Tris, pH 8.0, 4 mM MgCl2, 1% Triton 
X-100, and protease inhibitor cocktail [Roche]). Nuclei were removed by 
centrifugation, and postnuclear lysates were quantifi ed with a protein 
 assay (Bio-Rad Laboratories). 12 μg of each sample was separated by an 
8% SDS-PAGE and immunoblotted with an anti-Mfn2 antibody (Sigma-
 Aldrich), an anti-Mfn1 antibody (Chen et al., 2003), or anti–β-actin as a 
loading control. Mitofusin antibodies (diluted 1:1,000) were detected 
by HRP-conjugated secondary antibodies and ECL detection reagents 
(GE Healthcare).
Coimmunoprecipitation assay
Double Mfn-null cells were infected with retrovirus encoding Mfn1-3xHA or 
Mfn2-3xHA. Infected cells were selected by culture in media containing 
bovine calf serum, which does not support uninfected double Mfn-null cells. 
Each cell line was subsequently infected with virus encoding Mfn2-7xMyc 
constructs or Drp1-7xMyc. Postnuclear lysates were generated as  described 
above for MEFs (5–6 d after infection) and were immunoprecipitated with 
9E10 antibody coupled to protein A–Sepharose beads. HA.11 (Covance) 
and 9E10 antibodies were used for immunoblotting.
Online supplemental material
Fig. S1 shows the mitochondrial profi les of MEFs expressing Mfn2 CMT2A 
 alleles; this data is summarized in Fig. 1 C. Fig. S2 shows mitochondrial 
aggregation in MEFs highly overexpressing Mfn2 CMT2A alleles. Fig. S3 
shows that at low infection rates, recombinant Mfn2 is present at approxi-
mately fourfold the level of endogenous Mfn2. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.200611080/DC1.
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Supplementary Figures
Supplementary figure 1.  Mitochondrial profiles in MEFs expressing Mfn2 CMT2A
alleles.  A., Histogram of mitochondrial profiles in wild-type MEFs infected with mutant
Mfn2 retroviruses at low multiplicity of infection.  The percentage of cells with tubular
mitochondria presented in Figure 1C is the sum of the categories “all tubular,” “>50%
tubular” and “<50% tubular.”  For each histogram, at least 150 cells were scored.  B., As
in A, but in double Mfn-null MEFs.
Supplementary figure 2.  Mitochondrial aggregation in wild-type cells highly over-
expressing Mfn2 CMT2A alleles.  A., Representative overlay images of wild-type MEFs
infected with mutant Mfn2-Myc retrovirus at a high multiplicity of infection.
Mitochondria are visualized by matrix-targeted EGFP (green), and Mfn2-expressing cells
are identified by immunofluorescence against the Myc epitope (red).  Note the extensive
mitochondrial aggregation caused by some of the CMT2A alleles.  B., Histograms of
mitochondrial morphology in these cells.  For each histogram, at least 200 cells were
counted.  Scale bar = 10 microns.
Supplementary figure 3.  Quantification of retroviral expression levels.  Double Mfn-
null cells were infected at low multiplicity of infection with retrovirus expressing Mfn2-
HA.  Mfn2-HA expressing cells have a growth advantage compared to double Mfn-null
cells and form the bulk of the population after several passages.  Western blot analysis
with an anti-Mfn2 antibody was used to compare expression in infected cells with
90
endogenous Mfn2 expression.  The Mfn2 band in infected cells is higher due to the HA
tag.  The positions of molecular weight markers (in kDa) are indicated.
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Chapter 4
Mitofusin 2 Disease Allele Causes Gait Defects and Axonopathy in Transgenic
Mouse Model of CMT2A
Scott A. Detmer, Christine Vande Velde, Don W. Cleveland, David C. Chan
Christine Vande Velde, PhD, is a postdoctoral scholar in Don Cleveland’s lab at the
Ludwig Cancer Institute, University of California, San Diego.  Christine instructed and
assisted me in motor root dissections and performed the motor neuron measurements and
imaging presented in figure 5 of this chapter.
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Introduction
Mitochondria are essential and highly dynamic organelles.  Mitochondria are
actively transported within a cell to regions of energy demand by specific anterograde
and retrograde motors (Chang et al., 2006; Pilling et al., 2006).  Mitochondrial
morphology is determined by balanced and opposing processes of fusion and fission.
Disruption of either mitochondrial transport or morphology dynamics has been
experimentally linked to neuronal dysfunctionin Drosophila (Guo et al., 2005; Li et al.,
2004; Stowers et al., 2002; Verstreken et al., 2005).  In each case, a decrease in the
number of mitochondria at synaptic regions results in synaptic dysfunction.  Mutations in
two mitochondrial fusion proteins, Mitofusin 2 and OPA1, cause human neuropathies
Charcot-Marie-Tooth disease and dominant optic atrophy, respectively (Delettre et al.,
2000; Zuchner et al., 2004).
Charcot-Marie-Tooth disease (CMT) is a common hereditary peripheral
neuropathy characterized by loss of distal sensory and motor function (Young and Suter,
2003).  CMT is progressive with variable age of onset, and most patients present
clinically with loss of muscle mass in the feet and lower leg that cause gait impairments.
There are two main classifications of CMT.  The first, type 1, is due to myelination
defects and is primarily caused by mutation of structural myelin proteins.  Type 2 is
caused by primary defects in axons.  The most common form of the axonal class is CMT
type 2A, caused by mutations in Mitofusin 2 (Zuchner et al., 2004).
Mitofusin are nuclearly encoded, mitochondrial integral outer membrane proteins
that are required for mitochondrial fusion in yeast and mammals (Griffin et al., 2006).
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Mitofusins have an N-terminal GTPase domain and two heptad-repeat domains, all of
which face the cytoplasm.  There are two mitofusin proteins in mammals, Mfn1 and
Mfn2.  Over forty mutations have been identified in Mitofusin 2 that cause dominantly
inherited CMT type 2A (Chung et al., 2006; Engelfried et al., 2006; Kijima et al., 2005;
Lawson et al., 2005; Verhoeven et al., 2006; Zuchner et al., 2006; Zuchner et al., 2004).
The majority of these are missense point mutations and most occur within or adjacent to
the GTPase domain.  To date, Mfn2 CMT2A alleles have only been studied in cell
culture.  Overexpression of a majority of tested alleles results in mitochondrial
aggregation as well as defects in mitochondrial transport in cultured dorsal root ganglion
neurons (Baloh et al., 2007; Detmer and Chan, 2007).  Some Mfn2 CMT2A alleles are
functional for mitochondrial fusion, whereas others are not (Detmer and Chan, 2007).
In order to study the in vivo effects of an Mfn2 CMT2A allele, we generated
transgenic mice expressing Mfn2 T105M under control of a motor neuron specific
promoter.  We confirmed motor neuron expression and find that animals homozygous for
the transgene have hindlimb gait impairments, decreased hindlimb muscle mass and a
decrease in motor neuron axons.  Additionally, we find that mitochondrial morphology in
neurons is both aggregated and irregularly distributed.
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Results
Generation of Mfn2 T105M transgenic mouse
Charcot-Marie-Tooth Disease Type 2A (CMT2A) causes specific loss of long
motor and sensory neurons due to mutations in Mitofusin 2 (Mfn2).  To investigate the
effect of an Mfn2 CMT2A allele in motor neurons, we generated transgenic mice
expressing Mfn2 T105M 7xMyc under the control of the HB9 promoter.  Mfn2 T105M
has been found in three unrelated CMT2A families and has an early onset of foot and leg
muscular atrophy and additional features of scoliosis and ataxia (Chung et al., 2006;
Lawson et al., 2005; Zuchner et al., 2004).  The Mfn2 T105M allele localizes normally to
mitochondria and is non-functional for mitochondrial fusion (Detmer and Chan, 2007).
Similar to other Mfn2 CMT2A alleles, Mfn2 T105M induces mitochondrial aggregation
when overexpressed (Baloh et al., 2007; Detmer and Chan, 2007).  Position T105 is in
the middle of the GTPase G1 motif (103GxxxxGKS110) (Bourne et al., 1991).
HB9 is required embryonically for motor neuron identity determination and
consolidation (Arber et al., 1999; Thaler et al., 1999).  The HB9 promoter has been used
as a reliable indicator of motor neuron cells as extensively detailed in HB9-EGFP
transgenic mice (Wichterle et al., 2002).  The transgenic construct we generated consists
of the HB9 promoter driving expression Mfn2 T105M 7xMyc followed by an IRES and
EGFP (Fig. 1A).  We added the C-terminal Myc tag in order to label mitochondria in
motor neurons by immunofluorescence.  The IRES EGFP was included in order to label
motor neurons and their processes with cytoplasmic EGFP.
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Linearized transgene was injected into oocytes that were implanted into
pseudopregnant surrogates.  Founder animals were genotyped for the presence of the
transgene and test mated to verify propagation of the transgene.  Genotyping consisted of
a PCR reaction spanning a small intron such that amplification from the genomic Mfn2
locus results in a larger product than from the Mfn2 transgene, which lacks introns (Fig.
1B).  The reliability of this genotyping strategy was confirmed by agreement between
genotyping results and embryonic protein lysates probed with Myc antibody (Fig. 1B).
We determined the genomic integration site for an interesting line of HB9-Mfn2
T105M transgenic mice, hereafter referred to as Tg1.  The transgene integrated line Tg1
in a non gene-coding region on chromosome 11 between genes Rad51c and Ppm1e.  This
integration site was confirmed using PCR oligos at both the 5’ and 3’ ends of the
transgene (Fig. 1C).  Identifying the transgene integration site allowed us to distinguish
between heterozygous and homozygous Tg1 animals using PCR (Fig. 1C).
Hindlimb defect in Tg1/Tg1 animals
We noted that mice heterozygous for Tg1 were born with tails that were shorter
than wild-type animals and had bony kinks or thickenings (Fig. 2A,B).  When we mated
heterozygous Tg1 animals, approximately one-fourth of the progeny had extremely short
tails.  We confirmed that the short-tailed animals were homozygous for the transgene
using the PCR assay (Fig 1D).  This tail phenotype allowed for visual genotyping of the
Tg1 line.
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Tg1 homozygous animals have hindlimb and gait defects, evident from birth (Fig.
2A).  Young animals have hindpaws that appear limp due to a failure to dorsi-flex (Fig.
2D). When at rest, severely effected animals often fail to bring their hindpaws under their
haunches and instead leave their hindlimbs extended behind their bodies.  Tg1/Tg1 are
active and can move effectively, though they use their hindlimbs in the extended trailing
position in short push motions (Fig. 2E).  In addition, Tg1/Tg1 animals commonly have
hindpaws that are clenched and an apparent inability to spread their toes (Fig. 2F).
The severity of the hindlimb defect is variable between animals and is not
absolute in all Tg1/Tg1 animals.  Of 85 Tg1/Tg1 animals, 60% were bilaterally affected,
26% had only a single hindpaw with the defect and 14% had apparently normal hindpaws
and gait.  No hindpaw defects are observed in heterozygous animals, even at one year of
age.   Both Tg1/+ and Tg1/Tg1 animals live greater than 1 year and are fully fertile.
Tg1/Tg1 have an approximate 15% reduction in body weight at weaning (P20).  The
hindpaw/gait defect does not appear to worsen with age and no defect was observed in
the forelimbs.  Tg1/Tg1 performed well on rotorod tests and could manage traversing a
thin beam (data not shown).  These surprising results are perhaps explained by their
retention of sensory neurons that are important for determining foot placement.
The tail defects in the Tg1 animals are a consequence of the transgene and not the
integration site.  We generated compound heterozygotes with a second transgenic line of
HB9 Mfn2 T105M animals (Tg2) that have normal tails.  Tg1/+; Tg2/+ animals had
intermediate tail defects:  the tails of compound heterozygote animals were of
intermediate length between Tg1/+ and Tg1/Tg1 animals (Supp. Fig. 1).  Tg1/+; Tg2/+
had no hindlimb phenotype.  This suggests that the transgene expression level is critical
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for the observed phenotype and that only Tg1/Tg1 animals achieve this critical
expression level.  We do not know the basis of the tail defect in the Tg1 mice but it may
be related to transient HB9 expression in tail mesoderm (H. Wichterle, personal
communication).
Mfn2 T105M 7xMyc expression in motor neurons
We tested for motor neuron transgene expression in embryos and neonates.  As a
control, we examined day 12.5 HB9-EGFP embryos by cryosection.  As expected, motor
neurons are found in the ventral section of the developing spinal column and axons can
be observed traveling into the body of the embryo (Fig. 3A).  Similarly, in Tg1/Tg1 e12.5
embryos, we find ventral motor neuron EGFP signal.  These sections were also stained
using Myc immunofluorescence to identify mitochondria.  Myc staining is confined
within EGFP staining, consistent with our expectations (Fig. 3B).  We note that in these
cryosection images mitochondria have an aggregated appearance.
We next examined transgene expression in newborn animals (P0).  P0 pups were
transcardially perfused and their upper spinal cord dissected and cryosectioned.  Spinal
chord cross sections of HB9-EGFP control animals reveal motor neuron cell bodies in the
ventral horns (Fig. 3C). Tg1/Tg1 pups had similar EGFP staining and Myc
immunofluorescence was contained within EFGP-positive cell bodies (Fig. 3D).  We note
that in these samples mitochondria appear more tubular and distributed than in the e12.5
sections.
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HB9 is expressed embryonically coincident with motor neuron formation (Arber
et al., 1999; Thaler et al., 1999).  To follow post-natal HB9 transgene expression, we
made spinal cord lysates from P0, P2, P4, P6, P10 and P22 animals.  We checked
transgene expression using a Myc antibody and as a control for the HB9 promoter probed
GFP expression in HB9-EGFP pups.  Loads were normalized for protein level.  Both
GFP and Mfn2-Myc showed similar patterns of expression, with expression levels
apparently dropping off during the first week after birth and undetectable in spinal cord
lysates by three weeks of age.  These data demonstrate Tg1 has similar expression pattern
to HB9-EGFP, both in terms of motor neuron expression and expression timecourse.
We also examined the differences in transgene expression level in Tg1/+ and
Tg1/Tg1 animals at P0 and P8.  As expected, Tg1/Tg1 is expressed at levels
approximately twice that of Tg1/+ as judged by Myc intensity in spinal cord lysates.
These results are consistent with the expectation that the hindlimb phenotype correlates
with transgene expression level.
Musculature defects in Tg1/Tg1 animals
Given the hindlimb specific defect in the Tg1/Tg1 animals, we investigated the
musculature of the lower leg.  Compared to wild-type and Tg/+ animals, Tg1/Tg1
animals have dramatically reduced anterior musculature of the lower leg that is readily
visualized once the skin is removed.  In contrast, the posterior calf muscle mass appear
comparable across all genotypes.  To quantify these observations, we dissected and
weighed anterior and posterior muscles of the distal hindlimb.  Muscles groups were
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identified by their consistent distal tendon insertion site—the tendons were cut here,
lifted away from the limb and severed at the proximal attachment site (Fig. 4A).  This
technique allowed for reproducible isolation of the same muscle in different animals
despite differences in muscle size.  We found that the masses of posterior calf muscles (as
a fraction of animal body weight) were comparable in +/+, Tg/+ and Tg/Tg animals when
assessed at P22 (Fig. 4B,C).  In contrast, anterior muscles were comparable in +/+ and
Tg/+, but dramatically less massive in Tg/Tg animals with affected hindlimbs (Fig. 4
B,C).  The loss of anterior musculature is responsible for the Tg/Tg hindlimb phenotype
described above because the anterior muscles of Tg/Tg unaffected (normal) hindlimbs
had variable, intermediate mass (Fig. 4C).
The loss of anterior muscles is consistent with the inability of affected
homozygous animals to dorsiflex (Fig. 2D).  Interestingly, weakness of the lower leg
anterior peroneal muscle is a common symptom in CMT patients.  CMT patients also
have foot deformities, such as pes cavus and claw toes, due to weakness of foot muscles
(Young and Suter, 2003).  When the skin is removed from the hindfoot, there is
obviously less musculature in affected Tg1/Tg1 animals compared to +/+ animals.
However, these muscles are small and difficult to dissect so we were unable to quantify
the differences.
Loss of motor neurons in adult animals
We directly investigated the possibility of motor neuron neuropathy in the
Tg1/Tg1 animals by counting motor neuron axons.  Motor neuron cell bodies reside in
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the ventral horns of the spinal cord and send their axons down the spinal column.
Bundles of axons exit the spinal column at junctions between the vertebrate and are
called roots.  For example, the bundle of axons that exits at the L5 vertebrate is called the
L5 motor root.  Motor roots of the lumbar spine innervate the hindlimbs.  Since each
motor neuron has one axon, and a particular motor root has a stereotypical number of
axons, counting the number of axons in a specific motor root allows comparison of the
number of intact motor neurons between different animals.
Six-week-old +/+, Tg1/+ and Tg1/Tg1 animals were transcardially perfused, and
their L5 motor and sensory roots were dissected.  Motor roots appeared smaller in
Tg1/Tg1 animals compared to +/+ and Tg1/+.  Roots were processed for plastic
embedding and thin sections were stained with toluidine blue to identify myelin
structures.  (Fig. 5A).  No defects in myelination are observed in Tg1/+ or Tg1/Tg1
animals.
There are ~40% fewer axons in both the L5 and L4 Tg1/Tg1 motor roots
compared to +/+ and Tg1/+ (Fig. 5B).  We noted that there appeared to be a greater
proportion of large caliber axons in the Tg1/Tg1 root than in the other samples (Fig. 5A).
We measured the diameter of all axons in the L5 motor root for several animals of each
genotype (Fig. 5C).   Wild-type and Tg1/+ mice have a bimodal distribution of small and
large diameter axons.  In contrast, Tg1/Tg1 animals have a relative decrease in small
caliber axons and a relative increase in large caliber axons.  We find the similar
differences in axon diameter distributions in L4 motor roots (data not shown).
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Mitochondrial aggregation and distribution defects in Tg1/Tg1 motor neurons
We investigated the morphology and distribution of mitochondria in Tg1/Tg1
motor neurons.  In fibroblasts, overexpression of Mfn2 T105M causes perinuclear
mitochondrial aggregation.  For the wild-type control, we isolated motor neurons from
HB9-EGFP embryos and infected them with lentiviral mito-dsRed.  In this way, motor
neurons were labeled with GFP, and a percentage of them had dsRed mitochondria.  We
found that mitochondria were concentrated in the motor neuron cell soma but also present
throughout long axonal projections (Fig. 6A).  Tg1/Tg1 motor neurons also expressed
GFP and we labeled mitochondria in these cells with indirect immunofluorescence
against Mfn2-Myc.  In contrast to wild-type neurons, mitochondria in Tg1/Tg1 motor
neurons appeared highly aggregated and largely confined to the cell soma.  Mitochondria
were poorly distributed in axons, and when present, appeared as small aggregates (Fig.
6A).  We quantitated these differences in mitochondrial distribution and found that Tg1/+
had an intermediate phenotype between +/+ and Tg1/Tg1.
Discussion
We have generated a transgenic mouse that recapitulates some aspects of Charcot-
Marie-Tooth Disease.  Motor neuron expression of the CMT2A disease allele Mfn2
T105M resulted in a mouse with hindfoot and hindlimb musculature defects, gait
impairment and axonopathy.  Significantly, it is the longest motor neurons that are
affected, as in CMT disease.  Unlike CMT, these defects are not progressive—animals
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exhibit the phenotype perinatally and do not noticeably worsen with age.  This suggests
that the axonopathy we observe occurs at a very young age, perhaps embryonically, and
agrees with the expression profiling of the HB9 promoter which turns on early and fades
in the first weeks after birth.
This is the first study to report the effect of Mfn2 CMT2A alleles in motor
neurons in vivo.  In cultured motor neurons expressing the Mfn2 T105M transgene we
find aberrant mitochondria morphology and distribution, including predominant
mitochondria aggregates present in the cell soma.  This is very similar to the
mitochondrial defect observed with other Mfn2 CMT2A alleles expressed in dorsal root
ganglion neurons (Baloh et al., 2007).  We propose that defects in mitochondrial
morphology cause motor neuron dysfunction, and subsequently degeneration, analogous
to the defects seen in flies or hippocampal neurons when mitochondrial dynamics are
disrupted by mutation of Drp1 (Li et al., 2004; Verstreken et al., 2005).
There are several unanswered questions regarding the phenotype observed in
these transgenic mice.  First, why are the anterior muscles of the lower hindlimb affected
whereas the posterior calf muscles are not?  This feature is remarkably similar what is
observed in CMT patients.  Second, when during development does the observed 40%
reduction in distal motor neurons occur?  Do these motor neurons send out axons and
then degenerate or are they never formed?  Third, what is the significance of the
increased representation of large diameter axons observed in Tg1/Tg1 motor neurons?
Does this represent a compensatory mechanism for reduced axon numbers or is there a
specific loss of small caliber axons?  Reported nerve biopsy data from CMT2A patients is
limited, but loss of large myelinated axons in sural has been observed in two early onset
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patients, though large axons were preserved in late onset patients (Chung et al., 2006;
Verhoeven et al., 2006).  It is not clear how these findings relate to our observations in
the Tg1/Tg1 motor roots.
The Tg1/Tg1 mice described here provide a mouse model for studying the effects
of altered mitochondrial morphology in mammalian motor neurons and the consequences
of early long motor neuron loss.  These mice may also serve as a suitable host for re-
innervation experiments using exogenous motor neurons.
Experimental Procedures
Generation of transgenic mice
Mfn2 T105M 7xMyc (Detmer and Chan, 2007) was cloned into an HB9-MCS-
IRES-GFP vector provided by the Jessell lab and verified by restriction digest mapping
and sequencing of the ligation junctions.  The HB9-Mfn2 7xMyc-IRES-EGFP construct
was linearized by XhoI digest, gel extracted, column purified, sterile filtered and
delivered to Caltech animal facility for pro-nuclear injection.  PCR genotyping for the
transgene used the following oligos as depicted in Figure 1:  A
(GCGCCTCTCTGTGCTAGTTG) and B (GTCTGCAGTGAACTGGCAAT).
The transgene insertion site in the Tg1 line was determined using a strategy
described previously (Li et al., 1999).  We cloned genomic sequence flanking the
transgene by digesting Tg1 genomic DNA with EcoRI (site is present in 3’ end of
transgene), self-ligated this material and using it as a template for PCR with transgene
GFP oligos.  We confirmed the integration site with oligos as depicted in Figure 1:  C
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(TGGGGTGTGCTTTATTGACA), D (CTGCTTTCATGCACACACCT), E
(CTGCTTTCATGCACACACCT) and F (GCCTTCTTGAGAACCTGTGC).
Cryosection and immunofluorescence
Midgestation e12.5 embryos were fixed in 4%PFA/PBS for two hours at 4 ˚C,
washed in PBS, incubated in 30% sucrose/PBS and frozen in OCT.  Embryos were
cryosectioned at –20 ˚C, air dried and then subjected to Myc immunofluorescence using
the 9E10 antibody and a Cy3-labeled secondary.  EGFP signal was enhanced with an
Alexa-488 conjugated anti-GFP antibody (Invitrogen).
Spinal cord lysates
The spinal cord between the lower neck and the lower rib cage was extruded with
PBS and immediately dounce homogenized in 1XTBS/1%TX-100/1X Protease inhibitor
cocktail (Roche).  Cleared lysate was quantified with the BioRad Protein Assay kit and
equivalent loads were analyzed by western blot.
Hindlimb muscle analysis
P22 animals were euthanized and the skin was removed from their hindlimbs.
Calf and anterior muscles were dissecting by cutting the distal tendon, pulling the muscle
away and cutting the proximal attachments.  Muscles were weighed immediately
following dissection.
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Motor root dissection and staining
L4 and L5 motor roots were dissected from perfused six week old animals.  Roots
were further fixed, negatively stained with osmium and embedded in epon plastic for thin
sectioning as described previously (Yamanaka et al., 2006).  Thin sections were stained
with toluidine blue.  Bioquant software was used to count and individually measure axon
diameters of motor roots.
Motor neuron cultures
Spinal columns were dissected from e12.5 embryos and dissociated using Papain
protease (Worthington).  Cultures were plated on coverslips treated with Matrigel (BD
Biosciences) and processed for immunofluorescence 48 or 72 hours later.  HB9-EGFP
cultures were infected with lentivirus encoding mitochondrially-targeted dsRed.  Tg1
cultures were probed with the anti-Myc antibody 9E10 and a Cy3 labeled secondary.
EGFP signal in both cultures was enhanced using an Alexa-488 conjugated anti-GFP
antibody (Invitrogen).  Motor neurons were cultured in media as described previously
(Wichterle et al., 2002).
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Figure Legends
Figure 4-1.  Generation of Mfn2 T105M transgenic mice.  A.  Schematic of transgene
construct depicting motor neuron specific HB9 promoter, C-terminally tagged Mfn2
T105M-7xMyc, internal ribosome entry site (IRES) and EGFP.  B.  PCR scheme for
detecting transgenic animals.  Primers A and B were designed to produce a product of
genomic Mfn2 product of 392bp and a transgene Mfn2 product of 159bp.  e12.5 embryos
from a mating between transgenic and wild-type (+/+) animals were genotyped (top
panel); in transgenic DNA samples, the smaller product is favored over the longer
endogenous product.  Spinal column lysates from the same embryos were analyzed for
Mfn2-Myc expression by western blot with a Myc antibody (bottom panel).  C.  The
transgene integration in the Tg1 line is on Chromosome 11 between the Rad51c and
Ppm1e genes; the transgene is depicted as a single dark arrow, though there are likely
multiple tandem transgene insertions.  The 5’ transgene insertion site was confirmed with
oligos CEF, where the wild-type product (EF) is 529bp and the Tg1 product (EC) is
279bp.  The 3’ integration site was confirmed with oligos DEF, where the Tg1 product
(DF) is 800bp.  Note the absence of wild-type product (EF) in Tg1/Tg1 samples and the
absence of Tg1 product (EC, DF) in +/+ and Tg2 (second transgenic line) samples.
Figure 4-2.  Tg1/Tg1 mouse phenotype.  A and B.  Tail defects in newborn (P0) (A) and
P8 (B) +/+, Tg1/+ and Tg1/Tg1 animals:  Tg1/+ animals have a shortened tail and
Tg1/Tg1 animals have a very short tail.  C and D.  Compare hindpaw posture in P8 wild-
type (C) and Tg1/Tg1 (D) animals (arrow). Tg1/Tg1 animal has limp hindpaws to due
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failure to dorsiflex the hindfoot.  E.  Frame from video of P8 Tg1/Tg1 animal walking.
Hindpaws are extended behind animal and used to push itself forward without retracting
under the body in normal steps.  F.  Clenched hindpaw in adult Tg1/Tg1 animal, detailed
in inset.
Figure 4-3.  Transgene expression in motor neurons.  A.  Cryosection of Tg1/Tg1 spinal
column showing GFP labeled motor neurons (green) and mitochondria labeled by anti-
Myc immunoflusoescence (red).  Right panel is magnified image of indicated region.  B.
Spinal cord cryosection from P0 Tg1/Tg1 animals, stained as in A.  C.  Expression
timecourse of HB9-Mfn2-Myc (top panels) and HB9-EGFP (bottom panels).  Two spinal
cord lysates were prepared from P0, P2, P4, P6, P10, and P22 Tg1/Tg1 and HB9-EGFP
animals, normalized by protein concentration and analyzed by western blot using Myc
(Tg1/Tg1) and GFP (HB9-EGFP) antibodies.  In both cases, a β-actin antibody was used
as a loading control.  D.  Comparison of Mfn2-Myc expression level in spinal cord
lysates from Tg1/+ and Tg1/Tg1 animals at P0 and P8.
Figure 4-4.  Hindlimb muscle mass.  A.  Schematic of hindlimb muscle dissection.
Anterior (a) and posterior (p) muscle groups were identified and severed at the tendon
sites indicated by the arrows.  B.  Images of dissected muscles from Tg1/+ and Tg1/Tg1
(bilaterally affected) animals.  Posterior muscles (p) are of comparable size in both
animals whereas anterior muscles (a) are severely atrophied in Tg1/Tg1 animals
compared to Tg1/+.  C. Quantitation of posterior and anterior muscle masses from +/+ (n
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=2),  Tg1/+ (n = 18), Tg1/Tg1 affected (n = 14) and Tg1/Tg1 unaffected (n = 8)
hindlimbs; the error bars indicate standard deviations.
Figure 4-5.  Loss of motor neurons in Tg1/Tg1 animals.  A.  Toluidine blue stained cross
section of motor neuron L5 roots from the indicated genotypes.  B. Quantitation of
number of axons in L5 and L4 motor roots.  Number (n) of roots counted for each
genotype is indicated in chart.  C. Distribution of motor neuron axon caliber in L5 roots.
The total number of axons having diameters of 0 - 0.5, 0.5 - 1, 1 - 1.5 microns, etc. are
indicated.  Inset shows percent of axons of a given caliber relative to total axons for each
genotype.
Figure 4-6.  Altered mitochondrial distribution in Tg1/Tg1 motor neurons.  A.  Images of
mitochondria in cultured motor neurons (MNs) derived from e12.5 mice.  +/+ MNs were
isolated HB9-EGFP mice and infected with lentiviral mito-dsRed.  Tg1/Tg1 MNs express
EGFP (from the transgene) and were stained by anti-Myc immunofluorescence to label
mitochondrial Mfn2-Myc.  Note that in +/+ MNs, mitochondria are distributed
throughout the axon; in contrast, in Tg1/Tg1 MNs, mitochondria are poorly distributed.
Tg1/Tg1 MNs also have aggregated mitochondria in the cell soma, but that is not
conveyed in these images because overexposure was necessary to reveal axonal
mitochondria.  B.  Quantitation of mitochondrial morphology and distribution in +/+ (n =
20), Tg1/Tg1 (n = 47) and Tg1/Tg1 (n = 65) motor neurons.
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Supplementary figure 4-1.  Transgene allelic series for tail phenotype.  The tails of P22
animals of the indicated genotypes are shown.  Note that the length of the Tg1/+; Tg2/+
tail is intermediate to the lengths of Tg1/+ and Tg1/Tg1 animal tails.  The genotype of
Tg1/+; Tg2/+ was confirmed by test mating.
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Chapter 5
Generation of Mitofusin 2 Knock-In Mouse Models of Charcot-Marie-Tooth
Disease Type 2A
Scott A. Detmer and David C. Chan
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Introduction
Mutations in the mitochondrial fusion factor Mitofusin 2 (Mfn2) cause axonal
Charcot-Marie-Tooth Disease Type 2A (CMT2A) (Zuchner and Vance, 2005).  CMT
disease is a progressive neuropathy that selectively effects the longest motor and sensory
neurons, causing muscle weakness and sensory loss in the feet and legs, which commonly
advances to the hands and forearms with age (Young and Suter, 2003).  The pathology in
CMT is divided between primary defects in myelination (type 1) or in the axon proper
(type 2).  Type 1 and type 2 can be distinguished clinically by nerve conduction velocities
and compound action potentials, or pathologically by nerve biopsy (Young and Suter,
2003).
Mfn2 CMT2A mutations are dominantly inherited.  The majority of the 45
CMT2A mutations identified in Mfn2 are missense point mutations and most occur
within or closely surrounding the GTPase domain (Chung et al., 2006; Engelfried et al.,
2006; Kijima et al., 2005; Lawson et al., 2005; Verhoeven et al., 2006; Zuchner et al.,
2004; Zuchner and Vance, 2005).  A subset of these alleles have been characterized in
cell culture overexpression studies and were found to be a mix of functional and non-
functional alleles that commonly cause mitochondrial aggregation (Baloh et al., 2007;
Detmer and Chan, 2007).  Importantly, wild-type Mfn1, but not wild-type Mfn2, can
functionally complement non-functional Mfn2 CMT2A alleles and this suggests that
expression of Mfn1 may play a role in the cell type specificity of this disease (Detmer
and Chan, 2007).  Work in Drosophila demonstrates that normal mitochondrial
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morphology and anterograde transport are required in neurons for proper synaptic
function (Guo et al., 2005; Stowers et al., 2002; Verstreken et al., 2005).
The role of Mfn2 in CMT2A disease progression and pathology is unknown.  For
example, what effects do the Mfn2 alleles have on mitochondrial morphology and
distribution in long motor and sensory neurons?  What is the basis for the cell type
specificity?  In addition, there are limited treatment options for CMT2A, and, more
broadly, for CMT disease and neuropathies in general.  In an attempt to address some of
these issues, we have generated knock-in mice for two Mfn2 CMT2A alleles.
Characterization of these mice is now underway and here we present preliminary results.
The key advantage of this approach over our transgenic mouse model of CMT2A
(chapter 4) is that the mutant Mfn2 alleles are expressed from the endogenous promoter,
thus ensuring normal expression level and tissue distribution.  Heterozygous knock-in
mice are genetically identical to CMT2A patients.
Results and Discussion
Generation of CMT2A knock-in mice
We generated knock-in mice for two Mfn2 CMT2A alleles, R94Q and L76P, by
homologous recombination.  Both R94Q and L76P are conserved between and human
and mouse Mfn2 and both occur in exon 4 of mouse Mfn2.  The R94 position is the most
commonly occurring CMT2A mutation reported and the L76P mutation has been
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identified in two distinct probands.  Previous analysis has identified R94Q as a loss-of-
function mutation, whereas L76P is capable of promoting mitochondrial fusion (Detmer
and Chan, 2007).  When overexpressed in wild-type or Mfn-null fibroblasts, both alleles
cause mitochondrial aggregation (Detmer and Chan, 2007).
Mfn2 L76P and Mfn2 R94Q were cloned into targeting vectors containing a loxP-
flanked neomycin cassette for positive selection and tetanus toxin for negative selection.
Cloning, homologous recombination, screening of embryonic stem (ES) cells and founder
mice, and Cre-mediated recombination has been described previously for Mfn2 R94Q
(Detmer and Chan, 2007).  Since L76 is in the same exon as R94, generation of the L76P
mouse was identical to R94Q, and is not detailed here.
ES cell differentiation to motor neurons
In vitro differentiation of mouse ES cells to motor neurons has been described
(Wichterle et al., 2002).  We used our ES cells in this differentiation assay to examine
mitochondrial morphology in motor neurons heterozygous for Mfn2 L76P and Mfn2
R94Q.  As a control for differentiation, we used HB9-EGFP ES cells that express EGFP
when they have attained motor neuron identity.  When mitochondria were stained with
MitoTracker Red, we found no differences in mitochondrial morphology or distribution
in motor neuron axonal processes between wild-type and Mfn2 L76P or Mfn2 R94Q
heterozygous cells (data not shown).  In all cases, mitochondria were short tubules and
present throughout the axon.  These results suggest that there is no gross defect in motor
neuron mitochondrial morphology induced by these CMT2A alleles.  This is not totally
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unexpected given that CMT2A disease is progressive and selectively affects the longest
neurons of the body.  In this assay, differentiated motor neurons were only several days
old and axonal processes were less than ~500 microns in length.
L76P and R94Q heterozygous mouse phenotypes
We observe no obvious phenotype in either L76P or the R94Q heterozygous
animals, the directly relevant genotype to human disease.  Even at one year of age,
heterozygous animals are similarly sized and as active and coordinated as wild-type
littermates when observed in their home cages and assessed by simple behavioral tests,
including suspending by tail, traversing their home cage rim, ability to hang onto inverted
cage top, and latency to paw flick in a hot plate assay (data not shown).  In this regard,
these Mfn2 CMT2A heterozygous animals are no different than the Mfn2 heterozygous
knock-out mice, which are similarly asymptomatic.
The phenotype of the Mfn2 CMT2A heterozygous animals need to be examined
more carefully for subtle or progressive defects by histology, for evidence of axonal
degeneration (e.g., of motor and sensory roots, as in chapter 4), and by functional testing,
for evidence of decreasing motor function with age (e.g., rotarod and gripstrength
measurements).  Lack of neuropathy in the CMT2A heterozygous animals may be due to
differences between human and mouse anatomy and physiology.  First, the longest
neurons in mouse are roughly 4 centimeters, whereas in humans they can reach one meter
in length.  Second, age of onset is variable in CMT2A patients but is rarely documented
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in patients less than 5 years of age; mice have only an approximate 2-year life span in
laboratory facilities.
Mitofusin gene dosage effects in CMT2A animals
We sought to elicit a phenotype in the CMT2A animals by altering the ratio of
mutant allele to total mitofusin levels.  Wild-type animals have 2 copies of Mfn1 and 2
copies of Mfn2; heterozygous R94Q and L76P animals have 2 copies of Mfn1, 1 copy of
wild-type Mfn2, and 1 copy of mutant Mfn2.  Because Mfn1 can uniquely complement
non-functional Mfn2 R94Q, we reasoned that altering the genomic ratios of Mfn1 and
Mfn2 in CMT2A animals might cause more severe defects.  Our lab has previously
generated knock-out mice for Mfn1 and Mfn2 and found that mice fully lacking either
mitofusin died as embryos, but that Mfn1 and Mfn2 null alleles could be carried in the
heterozygous state without having an effect on the animal (Chen et al., 2003).  We mated
Mfn1 (+/-) and Mfn2 (+/-) animals with our CMT2A animals.  We also mated our
CMT2A animals with each other to generate homozygous and mixed genotypes (Table I).
This strategy did not elicit an animal phenotype in the case of Mfn2 L76P.  We
detected no behavioral pathology in Mfn2 L76P homozygous animals or in any of the
genetic combinations tested (Table I).  As above, closer examination may reveal
histological or behavioral defects that distinguish these mice from simple Mfn2 L76P
heterozygotes.
We did find defects in Mfn2 R94Q animals when no wild-type Mfn2 was present.
Mfn2 R94Q homozygous (94Q/94Q) animals were born at expected ratios when R94Q
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heterozygous parents were mated.  At 5-6 days old, 94Q/94Q pups were obviously runted
compared to wild-type and R94Q heterozygous littermates.  This runting became more
severe as animals developed and the majority of 94Q/94Q animals were dead by 2 weeks
of age (Figure 1).  Despite their small size, 94Q/94Q runts appeared grossly normal but
had severe lack of overall musculature and had disproportionately smaller thymus and
pancreas compared to littermates.  94Q/94Q runts appeared dehydrated but were found to
have full stomachs when dissected.  One 94Q/94Q animal lived to three weeks of age and
had obvious movement defects—this animal would frequently trip and was generally
lethargic.  Younger 94Q/94Q animals exhibited frantic hindlimb flailing when suspended
by the tail, whereas littermates would simply slowly stretch their hindlimbs.  Similarly,
animals that had one Mfn2 R94Q and one Mfn2 knock-out allele (94Q/ko) also suffered
from severe runting.  These animals commonly survived to 3 weeks of age, on average
somewhat longer than 94Q/94Q animals.  94Q/ko animals also exhibited movement
defects.
The physiological cause of runting and early death in 94Q/94Q and 94Q/ko
animals remains to be determined.  Analysis of potential neuropathy is an obvious
starting point.  In preliminary studies, we found no evidence for loss on motor neuron cell
bodies in the spinal cord of 94Q/ko animals when stained with cresyl violet (data not
shown).  Histological analysis of thigh muscle fibers showed no alteration in COX
activity and no aberrant trichrome staining, suggesting that, at least in muscle, there are
not gross mitochondrial energetic defects (data not shown). A potential strategy to
determine tissues involved in the 94Q/ko phenotype is to use the Mfn2 conditional allele
(2C) (developed by H. Chen and D. Chan).  For example, use of tissue-specific Cre
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excision lines could be used with the 94Q/2C genotype to generate tissue-restricted
94Q/ko while the rest of the animal remains 94Q/2C.
It is significant that 94Q/94Q and 94Q/ko animals are born live.  Mice lacking
Mfn2 die in mid-gestation due to a placental defect (Chen et al., 2003).  Mfn2 R94Q is
non-functional for mitochondrial fusion when expressed alone, but can efficiently
promote mitochondrial fusion is the presence of Mfn1 (Detmer and Chan, 2007).  Thus,
the birth of 94Q/94Q mice indicates that these non-functional alleles can bypass the
placental defect of Mfn2-null embryos, likely by cooperating with Mfn1.  In a similar
situation, Mfn2 is required in Purkinje cells of the cerebellum and deletion of Mfn2 in
these cells causes Purkinje cell death, cerebellar atrophy and severe movement defects in
mice (H. Chen and D. Chan, manuscript in preparation).  We found that Purkinje cells in
94Q/ko animals were present at normal density and were part of an apparently healthy,
properly folded cerebellum (judged by calbindin and hemotoxylin/eosin staining, data not
shown).  Thus, as in the placental defect, Mfn2 R94Q has activity that is lacking in a null
Mfn2 allele.  Again, this activity is most likely due to complementation by Mfn1.
Mitochondrial morphology in CMT2A fibroblasts
Overexpression of C-terminally Myc tagged Mfn2 L76P or Mfn2 R94Q causes
mitochondrial aggregation (Detmer and Chan, 2007).  We generated mouse embryonic
fibroblasts (MEFs) that are heterozygous or homozygous for Mfn2 L76P or Mfn2 R94Q
to evaluate the mitochondrial morphology in cells expressing endogenous levels of Mfn2
CMT2A alleles.  We found that 76P/+, 94Q/+ and 94Q/94Q MEFs had wild-type
132
mitochondrial morphology distributions and essentially no mitochondrial aggregation
(Figure 2).  76P/76P MEFs also had normal mitochondrial morphology distributions plus
aggregated mitochondria in approximately 10% of cells (Figure 2).  Notably, Mfn2 L76P
was one of the few CMT2A alleles that induced mitochondrial aggregation even when
over-expressed at low levels (approximately fourfold endogenous levels) (Detmer and
Chan, 2007).  Though we realize that a morphology found in MEFs may not be relevant
in other cell types, these results motivate investigation of mitochondrial morphology and
distribution in neurons of Mfn2 L76P homozygous animals.  For example, electron
microscopy can be used to examine mitochondria in axonal cross-sections or specifically
at distal synaptic junctions.  Additionally, we will monitor the Mfn2 L76P homozygous
animals as they age for any emerging phenotypes that may be related to aggregated
mitochondria.
Assessing mitochondrial fusion competency of endogenous Mfn2 L76P and R94Q alleles
We previously determined that Mfn2 L76P was functional for mitochondria
fusion and Mfn2 R94Q was non-functional for mitochondrial fusion by expressing Myc-
tagged recombinant constructs in Mfn-null cells and assaying for mitochondrial fusion in
the PEG fusion assay (Detmer and Chan, 2007).  To unequivocally determine the fusion
capability of these alleles, we want to test endogenously expressed Mfn2 L76P and R94Q
in the mitochondrial fusion assay, thereby alleviating any concerns of expression level or
epitope tag effecting fusion activity.  To generate cell lines containing only mutant Mfn2
(and no wild-type Mfn1 or Mfn2), we mated the CMT2A knock-in mice with mice that
133
have conditional Mfn1 and Mfn2 alleles (1C and 2C) (developed by H. Chen and D.
Chan).  These conditional Mfn alleles can be deleted from the genome by Cre
recombinase.  We have generated the following CMT2A MEF cell lines:  C1/C1; C2/76P
and C1/C1; C2/94Q, and the following control MEF lines: C1/C1; C2/2 and C1/C1;
C2/C2.  The plan is to transiently transfect these cells with Cre-GFP, FACS sort for GFP-
expressing cells, confirm excision of conditional alleles in the sorted cells, and test all
cell lines in the mitochondrial fusion assay.
Perspectives
We have generated Mfn2 L76P and Mfn2 R94Q knock-in mice in an attempt to
model the progressive peripheral axonal neuropathy CMT2A.  Despite not having an
obvious neuropathy phenotype as heterozygous mutants, these animals should prove
useful to the CMT and mitochondrial morphology research communities.  First, these
animals await a full neurological evaluation and may well exhibit histological neuropathy
that has not been detected functionally.  We will continue to age and analyze the
heterozygotes.  If defects are detected, these animals could potentially be used for
designing therapeutic interventions for CMT and other neuropathies.  For example, it
would be interesting to test if neuronal expression of Mfn1 could rescue defects in Mfn2
R94Q animals, as we hypothesized (Detmer and Chan, 2007).  Second, the severe
phenotype found in the 94Q/94Q and 94Q/ko animals provides an animal reagent for
defining critical contributions of Mfn2 in developing mammals.  These animals also
provide in vivo evidence for complementation between Mfn1 and fusion-defective Mfn2.
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Finally, some of these animals (e.g., 76P/76P) may provide means to assess the effects of
altered mitochondrial morphologies (e.g. aggregation) in vivo, either by electron
microscopy or time-lapse visualization of mitochondria in living tissue.
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Figure Legends
Figure 5-1.  94Q/94Q animals have runted phenotype.  12-day-old pups from a mating of
heterozygous 94Q mice.  The mouse on the left, 94Q/94Q, is dramatically smaller than its
normally sized littermate, +/+ or 94Q/+.
Figure 5-2.  Mitochondrial morphologies in CMT2A MEFs.  Quantitation of
mitochondrial morphology in MEFs of the indicated genotypes.  For each genotype,
greater than 150 cells from three independently derived cell lines were scored between
passages 5 and 8.  The large standard deviation error bars reflect variability that is
commonly observed in early passage, independent cell lines; however, all cell lines
clearly have predominantly tubular mitochondrial morphologies.  Mitochondrial
aggregation was scored independent of morphology in the cell lines listed and is
tabulated below the chart; aggregation in 94Q/94Q cell lines was not scored directly, but
it was noted that aggregation occurred rarely (less than 5% of cells).
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Table 5-1
*total number of animals generated
**age of oldest animals attained of given genotype
***ko:  knock-out(null) allele
Phenotype (maximum age**)N*
many
many
>15
none detected (14 months)
none detected (13 months)
none detected (5 months)
none detected (8 months)
none detected (5 months)
none detected (3 months)
none detected (14 months)
none detected (3 months)
severe runting, movement defects, die at ~P14
severe runting, movement defects, die at ~P20
genotype
Mfn1
+/+
+/ko
Mfn2
76P/+
76P/76P
76P/ko***+/+
+/+
76P/+
+/ko 76P/76P
+/ko 76P/ko
94Q/+
94Q/94Q
94Q/ko
+/+
+/ko
+/+
+/+
94Q/+
+/+ 76P/94Q none detected (13 months)
7
9
3
3
>10
>10
5
3
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Chapter 6
Future Directions
Though a great deal of progress has been made since the identification of the first
mitochondrial fusion factor ten years ago, the field of molecular mitochondrial dynamics
is still in its infancy (Hales and Fuller, 1997).  Key avenues of research for the future
include identification of additional mitochondrial morphology factors, mechanistic
studies of known factors and construction of relevant animal models of mitochondrial
diseases to learn about in vivo mitochondrial dynamics and disease progression.
Mammalian mitochondrial fusion
Mitochondrial fusion is most completely understood in yeast due to the
identification of essential factors by genetic screens.  The study of mitochondrial fusion
in mammals has been guided by homology to proteins in the yeast system and thus
largely confined to study of Mitofusins and OPA1.  Other yeast mitochondrial fusion
proteins such as Ugo1 have no obvious mammalian homologs.  However, in both yeast
and mammals the precise molecular mechanisms of fusion remains a mystery.  A priority
for a more complete understanding of mammalian mitochondrial fusion is the
identification of additional fusion factors.  Because even a reduction in mitochondrial
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fusion is sufficient to alter mitochondrial morphology, expression knock-down
approaches are amenable to identifying putative fusion factors.  Genome-scale RNAi
visual screens for multiple cell types are now available (Echeverri and Perrimon, 2006;
Root et al., 2006) and may prove useful for identifying morphology factors, as visual
screens of knock-out yeast libraries have been (Altmann and Westermann, 2005; Dimmer
et al., 2002).  A second approach to discover additional mitochondrial morphology
factors is to identify proteins that interact with known fusion factors.  Several recent
reports have identified proteins that co-immunoprecipitate with Mitofusin 2 and are
putatively implicated in maintaining mitochondrial morphology (Eura et al., 2006; Hajek
et al., 2006; Nakamura et al., 2006).  An alternative unbiased and more sensitive
approach using multidimensional protein identification technology (MudPIT) has been
successfully used to identify yeast mitochondrial morphology factors (Graumann et al.,
2004; Griffin et al., 2005).  This approach has recently been employed to identify
Mitofusin interacting proteins (Z. Song and D. C. Chan, unpublished results).  It is likely
that identification of additional fusion factors will also contribute to the discovery of
mechanisms regulating mitochondrial dynamics, which are currently unknown.
A bottleneck in characterizing putative factors is validating their role in
mitochondrial fusion.  Mitochondrial morphology studies are not always straightforward
because overexpression of mitochondrial proteins can cause mitochondrial aggregation
independent of their normal function.  Similarly, RNAi knock-down experiments are
difficult to interpret in the absence of an antibody to determine the extent of expression
inhibition, a common situation when initially characterizing novel proteins.  Further
complicating matters, mitochondrial morphology is very sensitive to the expression level
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of some proteins.  For example, overexpression of the fusion factor OPA1 causes
mitochondrial fragmentation, which, taken alone, would suggest that it is involved in
mitochondrial fission (Chen et al., 2005).  Additionally, current mitochondrial fusion
assays are only semiquantitative, and it is difficult to characterize incremental defects in
mitochondrial fusion.  Thus, characterization of novel factors would benefit from a
mammalian in vitro mitochondrial fusion assay in which the reaction timecourse and
cytoplasmic variables could be tightly controlled.  In yeast, such an assay has clarified the
role of Mgm1 and Fzo1 in inner and outer-membrane fusion (Meeusen et al., 2006;
Meeusen et al., 2004).  Potentially even more advantageous would be development of an
in vitro lipid reconstitution system, as has benefited the study of SNARE proteins (Weber
et al., 1998).  A challenge to establishing such a system will be recreating the unique lipid
composition of mitochondrial membranes, which may be required for the fusion reaction
(discussed in chapter 1).
Molecular mechanism of Mitofusin function
The finding that Mitofusin 1 heptad-repeat 2 mediates trans mitochondrial
tethering was the first mechanistic description of Mitofusin function in mitochondrial
fusion (Koshiba et al., 2004).  It is not clear how such tethered structures progress to
mitochondrial fusion, or indeed if Mitofusins are involved in this transition, but any
structural rearrangements are very likely to depend on the GTPase domain (chapter 2).
Biochemical and structural characterizations will be important in determining additional
features of Mitofusin function.  My attempts at in vitro reconstitution of Mitofusin 1 N-
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and C-terminal interactions were largely thwarted by solubility issues with bacterially
expressed protein fragments.  Though refolded Mitofusin fragments appeared to interact
directly by elution profile shifts in size-exclusion chromatography, I could not
demonstrate GTP binding or GTPase activity in various GTPase domain contructs of
Mfn1, either in the presence or absence of C-terminal fragments (S. A. Detmer and D. C.
Chan, unpublished observations).  Insect or mammalian cell expression systems may
allow recovery of soluble Mitofusin domain fragments that would be amenable to
enzymatic and structural studies.  Other groups have reported GTPase activity for
Mitofusin proteins but these studies were based on crudely purified full-length molecules
and, in the absence of GTPase-defective mutants, difficult to interpret (Ishihara et al.,
2004; Neuspiel et al., 2005).
Yeast have a single Mitofusin that functions as an oligomer (Griffin and Chan,
2006).  Mammals have two closely related mitofusins, Mfn1 and Mfn2, which form both
homooligomers and heterooligomers (Mfn1/Mfn1, Mfn2/Mfn2, Mfn1/Mfn2) (Chen et al.,
2003).  Each of these trans oligomers can promote mitochondrial fusion, but it is not
clear if there are functional distinctions between them (Chen et al., 2005).  Our
observation that wildtype Mfn1, but not Mfn2, can complement non-functional Mfn2
Charcot-Marie-Tooth disease mutations demonstrates functional differences between
Mfn2/Mfn2 and Mfn1/Mfn2 oligomers (chapter 3).  Construction of chimeric Mfn1/2
molecules could be used to uncover the sequence requirements of this unique
complementation.  Again, an in vitro mitochondrial fusion assay may provide a
quantitative way to assess different functional activities of the three Mitofusin oligomers.
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Animal models of mitochondrial diseases
Mitochondrial dysfunction is the basis of several hereditary and spontaneous
diseases, including mental illness, metabolic diseases, neuropathies and ageing (Lin and
Beal, 2006).  These diseases can be caused by mutations in mitochondrial DNA,
oxidative phosphorylation proteins or mitochondrial morphology proteins, such as OPA1,
Mfn2 and GDAP1 (discussed in chapter 1) (Delettre et al., 2000; Niemann et al., 2005;
Zuchner et al., 2004).  In general, these diseases are progressive in nature, manifest as
modest physical limitations, and generally do not grossly compromise life expectancy.
These reasons have made it difficult to generate mouse models of mitochondrial disorders
because the most useful animal phenotype is one that is mechanistically relevant to the
disease state and (1) not so severe that the animals cannot develop into adults and
propagate and (2) not so mild that phenotypes only appear at late age.
A clear success in modeling mtDNA mutations is the proofreading-deficient
mtDNA polymerase PolgA mouse that has a dramatic premature ageing phenotype
coincident with accumulating mtDNA mutations and deletions (Trifunovic et al., 2004).
Attempts to model CMT disease have been more difficult.  Our transgenic Mfn2 T105M
and homozygous Mfn2 R94Q knock-in animals have more severe phenotypes than are
found with the disease (chapter 5).  In other situations, CMT models have effects that are
too mild.  For example, mouse models of Mtmr2 mutations in CMT4B1 result in animals
with only very subtle defects that manifest at late age and can only be scored by
histological criteria (Bolino et al., 2004; Bonneick et al., 2005).  This is likely a similar
situation to our heterozygous Mfn2 knock-in animals (chapter 5).  Future studies with
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theses apparently asymptomatic animals should try to elicit phenotypes.  For example, if
low levels of neuropathy or slightly compromised motor function are present, conditions
of heavy or continual exercise may unveil relevant phenotypic defects.  Alternatively,
animals could be reared under conditions that demand greater mitochondrial function, for
example, at slightly reduced temperatures or with low levels of dietary oxidative
phosphorylation uncouplers.
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